WO2024028795A1 - Heterobicyclic compounds as oral glp1r agonists - Google Patents
Heterobicyclic compounds as oral glp1r agonists Download PDFInfo
- Publication number
- WO2024028795A1 WO2024028795A1 PCT/IB2023/057846 IB2023057846W WO2024028795A1 WO 2024028795 A1 WO2024028795 A1 WO 2024028795A1 IB 2023057846 W IB2023057846 W IB 2023057846W WO 2024028795 A1 WO2024028795 A1 WO 2024028795A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- oxy
- benzo
- imidazole
- fluorobenzyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title claims description 9
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 127
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- -1 (S)-2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid Chemical compound 0.000 claims description 504
- 238000000034 method Methods 0.000 claims description 110
- 239000002904 solvent Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 15
- 230000001771 impaired effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 208000035180 MODY Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims description 5
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 4
- 208000010444 Acidosis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 3
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 206010056465 Food craving Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 3
- 201000001431 Hyperuricemia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 208000007976 Ketosis Diseases 0.000 claims description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000001280 Prediabetic State Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000021017 Weight Gain Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000010014 adipocyte dysfunction Effects 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000019771 cognition Effects 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000008694 endothelial dysfunction Effects 0.000 claims description 3
- 208000004104 gestational diabetes Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 230000004153 glucose metabolism Effects 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 230000004140 ketosis Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 230000000291 postprandial effect Effects 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 230000036269 ulceration Effects 0.000 claims description 3
- 230000009278 visceral effect Effects 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 2
- 229940127254 ASK1 inhibitor Drugs 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 2
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims description 2
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims description 2
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims description 2
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 101150113964 MPK5 gene Proteins 0.000 claims description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 claims description 2
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims description 2
- HYHMLYSLQUKXKP-UHFFFAOYSA-N bempedoic acid Chemical compound OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O HYHMLYSLQUKXKP-UHFFFAOYSA-N 0.000 claims description 2
- 229950002974 bempedoic acid Drugs 0.000 claims description 2
- 239000003858 bile acid conjugate Substances 0.000 claims description 2
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims description 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 claims description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract description 9
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract description 9
- 230000008484 agonism Effects 0.000 abstract description 6
- 230000037396 body weight Effects 0.000 abstract description 4
- 239000013585 weight reducing agent Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 146
- 238000003786 synthesis reaction Methods 0.000 description 109
- 230000015572 biosynthetic process Effects 0.000 description 108
- 239000011541 reaction mixture Substances 0.000 description 91
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 82
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 72
- 239000000243 solution Substances 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 235000019439 ethyl acetate Nutrition 0.000 description 55
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- 239000000543 intermediate Substances 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 36
- 229910000027 potassium carbonate Inorganic materials 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 28
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 235000015320 potassium carbonate Nutrition 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- SLQIJFSQRNXACV-JTQLQIEISA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC SLQIJFSQRNXACV-JTQLQIEISA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 239000012267 brine Substances 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- LVQFHDAKZHGEAJ-UHFFFAOYSA-M 4-methylbenzenesulfonate Chemical compound [CH2]C1=CC=C(S([O-])(=O)=O)C=C1 LVQFHDAKZHGEAJ-UHFFFAOYSA-M 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000013058 crude material Substances 0.000 description 12
- VYDXRLUAPZZPEZ-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-(2-methoxyethyl)benzimidazole-5-carboxylate Chemical compound COCCN1C(CCl)=NC2=C1C=C(C=C2)C(=O)OC VYDXRLUAPZZPEZ-UHFFFAOYSA-N 0.000 description 12
- 235000011181 potassium carbonates Nutrition 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 6
- YGAURRAHPYQHDC-UHFFFAOYSA-N 3-fluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=C(C#N)C=C1F YGAURRAHPYQHDC-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- XUZRWKWJKDCQNA-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1F XUZRWKWJKDCQNA-UHFFFAOYSA-N 0.000 description 4
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 4
- CIFFBTOJCKSRJY-UHFFFAOYSA-N 3α,4,7,7α-tetrahydro-1h-isoindole-1,3(2h)-dione Chemical compound C1C=CCC2C(=O)NC(=O)C21 CIFFBTOJCKSRJY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- JJNKKECPOPWYNY-UHFFFAOYSA-N (5-chloropyridin-2-yl)methanol Chemical compound OCC1=CC=C(Cl)C=N1 JJNKKECPOPWYNY-UHFFFAOYSA-N 0.000 description 3
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 3
- NPEIUNVTLXEOLT-UHFFFAOYSA-N 2-chloro-1,1,1-trimethoxyethane Chemical compound COC(CCl)(OC)OC NPEIUNVTLXEOLT-UHFFFAOYSA-N 0.000 description 3
- DMZFOGQBUVKGIO-UHFFFAOYSA-N 3,4-bis(bromomethyl)-1-(4-methylphenyl)sulfonylpyrrole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C=C(CBr)C(CBr)=C1 DMZFOGQBUVKGIO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- WCHUSHMDTHFDQT-UHFFFAOYSA-N [4-(hydroxymethyl)-1-(4-methylphenyl)sulfonylpyrrol-3-yl]methanol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C=C(CO)C(CO)=C1 WCHUSHMDTHFDQT-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- MMEZYVIPIWHMED-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylate Chemical compound CCN1C(CN2C(C=C(C=C3)C(OC)=O)=C3N=C2CCl)=CN=C1 MMEZYVIPIWHMED-UHFFFAOYSA-N 0.000 description 3
- YSLWOAWEVXQWPB-QMMMGPOBSA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylate Chemical compound ClCC1=NC=2C(=NC(=CC=2)C(=O)OC)N1C[C@H]1OCC1 YSLWOAWEVXQWPB-QMMMGPOBSA-N 0.000 description 3
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 3
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- IBUNCTVDGYIKAP-UHFFFAOYSA-N tert-butyl 4,6-dihydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxylate Chemical compound C1=NNC2=C1CN(C(=O)OC(C)(C)C)C2 IBUNCTVDGYIKAP-UHFFFAOYSA-N 0.000 description 3
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- NTZXBJJNAKCVQO-BYPYZUCNSA-N (2S)-2-(azidomethyl)oxetane Chemical compound N(=[N+]=[N-])C[C@H]1OCC1 NTZXBJJNAKCVQO-BYPYZUCNSA-N 0.000 description 2
- LMLDXXXZBRCPIP-NSHDSACASA-N (2s)-2-(phenylmethoxymethyl)oxetane Chemical compound C([C@H]1OCC1)OCC1=CC=CC=C1 LMLDXXXZBRCPIP-NSHDSACASA-N 0.000 description 2
- VRNDVSYJBCTFPF-UHFFFAOYSA-N 1,3-thiazol-5-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CN=CS1 VRNDVSYJBCTFPF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HWZHYUCYEYJQTE-UHFFFAOYSA-N 2,3,3a,4,7,7a-hexahydro-1h-isoindole Chemical compound C1C=CCC2CNCC21 HWZHYUCYEYJQTE-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical compound CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- NTDFYGSSDDMNHI-UHFFFAOYSA-N 2-ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC(S(=O)CC)=NC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 NTDFYGSSDDMNHI-UHFFFAOYSA-N 0.000 description 2
- BSCXJGYBFUSMSF-UHFFFAOYSA-N 4-[(6-chloropyridin-2-yl)oxymethyl]-3-fluorobenzonitrile Chemical compound ClC1=CC=CC(=N1)OCC1=C(C=C(C#N)C=C1)F BSCXJGYBFUSMSF-UHFFFAOYSA-N 0.000 description 2
- XKWZJTLSKYAKFQ-UHFFFAOYSA-N 5-(azidomethyl)-1,3-thiazole Chemical compound [N-]=[N+]=NCc1cncs1 XKWZJTLSKYAKFQ-UHFFFAOYSA-N 0.000 description 2
- KRCJWYXQNALNSP-UHFFFAOYSA-N 6-(hydroxymethyl)pyridine-3-carbonitrile Chemical compound OCC1=CC=C(C#N)C=N1 KRCJWYXQNALNSP-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- NALKUTSPQGNISH-YFKPBYRVSA-N [(2S)-oxetan-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OC[C@H]1OCC1 NALKUTSPQGNISH-YFKPBYRVSA-N 0.000 description 2
- QDEFNAHLCTUWAH-BYPYZUCNSA-N [(2s)-oxetan-2-yl]methanamine Chemical compound NC[C@@H]1CCO1 QDEFNAHLCTUWAH-BYPYZUCNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 2
- XVGRXGAVTAFONQ-UHFFFAOYSA-N dimethyl 1-(4-methylphenyl)sulfonylpyrrole-3,4-dicarboxylate Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)N1C=C(C(=C1)C(=O)OC)C(=O)OC XVGRXGAVTAFONQ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- CEYHKCZODRRMMV-VIFPVBQESA-N methyl 4-amino-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 CEYHKCZODRRMMV-VIFPVBQESA-N 0.000 description 2
- HTYWVEUBCLGQES-VIFPVBQESA-N methyl 4-nitro-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 HTYWVEUBCLGQES-VIFPVBQESA-N 0.000 description 2
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 2
- PQZJTHGEFIQMCO-UHFFFAOYSA-N oxetan-2-ylmethanol Chemical compound OCC1CCO1 PQZJTHGEFIQMCO-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- QNYBOILAKBSWFG-SNVBAGLBSA-N (2s)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-SNVBAGLBSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- XDNQVUAKCAPBIG-UHFFFAOYSA-N 1,3-thiazol-5-ylmethanamine Chemical compound NCC1=CN=CS1 XDNQVUAKCAPBIG-UHFFFAOYSA-N 0.000 description 1
- WKBQQWDVVHGWDB-UHFFFAOYSA-N 1,3-thiazol-5-ylmethanol Chemical compound OCC1=CN=CS1 WKBQQWDVVHGWDB-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RIGIUTCJAUSCIB-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CC(CC(O)=O)C(CC(O)=O)C1 RIGIUTCJAUSCIB-UHFFFAOYSA-N 0.000 description 1
- IMPKJSQQODOLEQ-UHFFFAOYSA-N 3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2N(CCOC)C=NC2=C1 IMPKJSQQODOLEQ-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056448 human GLP1R Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 239000010805 inorganic waste Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- GGNDIMLSSMWKDR-DTORHVGOSA-N tert-butyl (3ar,6as)-5-oxo-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(=O)C[C@H]2CN(C(=O)OC(C)(C)C)C[C@H]21 GGNDIMLSSMWKDR-DTORHVGOSA-N 0.000 description 1
- PTUXVACHNRAHTJ-UHFFFAOYSA-N tert-butyl 5-(trifluoromethylsulfonyloxy)-3,3a,6,6a-tetrahydro-1h-cyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(OS(=O)(=O)C(F)(F)F)=CC2CN(C(=O)OC(C)(C)C)CC21 PTUXVACHNRAHTJ-UHFFFAOYSA-N 0.000 description 1
- GGNDIMLSSMWKDR-UHFFFAOYSA-N tert-butyl 5-oxo-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(=O)CC2CN(C(=O)OC(C)(C)C)CC21 GGNDIMLSSMWKDR-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention provides novel heterobicyclic compounds of general formula (I) and their salts that are useful for the treatment of diabetes mellitus, obesity and other metabolic disorders especially involving the agonism of the GLP1 receptor. Further, the present invention relates to processes of preparing such compounds, their novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
- GLP1 Glucagon Like Peptide 1
- GLP1 (7-36) is an endocrine hormone secreted by L cells of pancreas by the stimulation of food intake and other conditions. GLP1 peptide acts as an agonist to stimulate its receptor, GLP1R, to produce insulin and to inhibit glucagon production in a glucose dependent manner.
- GLP1R agonism has multiple physiological effects including gastric emptying, satiety, food intake, body weight loss etc. Because of these properties, GLP1R agonists like Exenatide, Liraglutide, and Semaglutide etc. are extensively used for the treatment of diabetes and obesity.
- Diabetes and Obesity are the two most common metabolic disorder diseases prevalent in modern lifestyle which are rapidly growing in all parts of the world. Diabetes is associated with hyperglycemia which further causes and becomes responsible for multiple diseases like diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic wound, hypertension, dyslipidemia, hyperinsulinemia etc. Obesity on the other hand is associated with insulin resistance, liver diseases (NAFLD, NASH) etc. Many GLP1R agonists have been disclosed in the literature - J. Med. Chem. 2022, Nature Medicine 2021, W02020103815, W02022031994, WO2021191812, WO2021118906, WO2021116874 and WO2020234726.
- novel compounds of general formula (I) which are oral GLP-1 agonist and are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.
- the present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.
- the main objective of the invention is to provide novel compounds of formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical composition comprising them or mixture thereof.
- the another embodiment of the invention is to provide a process for the preparation of compound of formula (I), process of their novel intermediates, their pharmaceutically acceptable.
- the further embodiment of the present invention is to provide the pharmaceutical compositions containing compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, in combination with suitable pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
- the yet another embodiment is to provide the use of the novel compounds of the present invention as anti-metabolic disorder agents, by administering a therapeutically effective & non-toxic amount of the compound as defined by the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical composition comprising them or mixture thereof .
- the compound of formula (I) can be administered in combination with other therapeutic agents.
- X represent N, CH or -CF
- Y represents hydrogen, halogen, -CN, alkyl and haloalkyl; m represents 1 , 2, 3 and 4.
- the groups referred to above may comprise of:
- Alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight- or branched- chain, fully saturated aliphatic hydrocarbon radical having the number of carbon atoms designated.
- “Ci-ealkyl” refers to a hydrocarbon radical, either straight- or branched-chain, that contains from 1 to 6 carbon atoms and that is derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
- Alkyl includes branched-chain isomers of straight- chain alkyl groups, such as isopropyl, t-butyl, isobutyl, sec-butyl, and the like.
- Halo or halogen by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl”, are meant to include an alkyl in which one or more hydrogen is replaced by halogen atoms that can be the same or different, in a number ranging from one up to the maximum number of halogens permitted e.g. for alkyl, (2m'+l), where m' is the total number of carbon atoms in the alkyl group.
- haloCi-galkyl is meant to include difluoromethyl, trifluoromethyl, 2,2,2- trifluoroethyl, 4-chlorobutyl, 3 -bromopropyl, and the like.
- haloalkoxy refers to an alkoxy radical substituted with one or more halogen atoms.
- the haloalkyl and haloalkoxy groups have from one to five or from one to three halogen atoms. Examples of haloalkoxy groups include difluoro methoxy and trifluoro methoxy.
- substituted means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
- substituted means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
- combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single tablet/capsule having a fixed ratio of active ingredients or in multiple, separate tablet/capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- terapéuticaally effective is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
- terapéuticaally acceptable refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- patient means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the patient is a human.
- Compounds of formula (I) may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
- the present invention is meant to comprehend all such isomeric forms of the compounds of formula (I), either as single species or mixtures thereof.
- tautomers Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula (I).
- DIPEA Disopropyl ethyl amine
- NaHCO Sodium bicarbonate hrs: Hour(s) rt : room temperature min: Minute(s) tRe t : Retention time
- T1D Type 1 Diabetes
- T2DM Type 2 Diabetes Mellitus
- NASH Nonalcoholic Steatohepatitis
- HPLC purity was determined by using Agilent 1100 instrument.
- Wave length UV at 220 nm.
- Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
- Preferred compounds according to the present invention include but are not limited to:
- compositions comprising compound of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
- diseases selected from T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma,
- compound of formula (I) of the present invention may be used in combination with one or more suitable pharmaceutically active agents selected from following therapeutic agents in any combination.
- Compound of formula (I) may appropriately combined with FXR agonist and semi-synthetic bile acid analogue, ACC inhibitor, Dual CCR2 and CCR5 antagonist, Thyroid hormone receptor beta agonist, MAPK5/ ASK-1 inhibitor, SGLT-2 inhibitor, Glucagon-like peptide-1 (GLP-1) receptor agonist, Glucagon-like peptide-1 (GLP-1) mimetics, PPAR a/5 agonist, Stearoyl Coenzyme A Desaturase 1 (SCD1) inhibition-Synthetic fatty acid-bile acid conjugate, Caspase inhibitor, metformin, sulfonyl ureas, long chain fatty acid agonists (GPR40, GPR120), DPP4 inhibitors, insulin sensitizer, Bempedoic acid or pharmaceutically acceptable salts thereof.
- the compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis or variation thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to those described below, where all symbols are as defined earlier.
- an intermediate like amine A was synthetized by multiple steps and similarly a chloro intermediate like B was also synthetized through multiple steps from commercially available starting material.
- the two intermediates A and B were then coupled in presence of an inorganic base like potassium carbonate to produce precursor compound C.
- the ester precursor C is then hydrolyzed in the presence of mild base DBU to provide final molecule D which was then purified and tested in different biological assays.
- the pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (I) with suitable acids in suitable solvents by processes known in the art.
- Step 8 Preparation of methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
- Methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (210 mg, 0.889 mmol) and 2- chl oro-1, 1,1 -trimethoxy ethane (151 mg, 0.978 mmol) was dissolved in Acetonitrile (5 ml) and catalytic amount of p- toluenesulfonic acid monohydrate (8.45 mg, 0.044 mmol) was added to it and reaction mixture was heated to 60 °C for 2 hrs. The reaction mixture was heated overnight.
- Reaction mixture was acidify with 10% citric acid solution. Extract the product with EtOAc (10 ml), wash with H2O (5 ml), brine (5 ml), dried over Na2SO4 and concentrate. Purified the product through combiflash to obtain (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin- 2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid ( 10 mg, 25.6% yield).
- Step-1 methyl2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
- Step-2 methyl(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3 ,4-c]pyrrol-2(l H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1H- benzo[d]imidazole-6-carboxylate
- Step-1 methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
- Step-2 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
- Step-2 methyl (S)-2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
- Step- 2 Synthesis of tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate
- Tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate was synthesized using tert-butyl 5-(2- chloropyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (400 mg, 1.239 mmol) in toluene (4 ml).
- Step 2 Synthesis of 5-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-l,2,3,5- tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2-trifluoroacetate)
- Step-1 2,3,3a,4,7,7a-hexahydro-lH-isoindole
- the reaction mixture was quenched with dropwise addition of ice water (75mL), while maintaining an internal temperature below 5 °C. Upon completion of water addition, the reaction mixture turned to a thick slurry. Additional THF (20ml) and solid sodium sulfate were added followed by dropwise addition of KOH solution (15%; 0.58g KOH in 3.8ml water), over a period of 20min, while maintaining an internal temperature below 5 °C. Additional water (10ml) and solid sodium sulfate (2 g) were added, and the reaction mixture was slowly warmed to room temperature. At room temperature it was stirred for another 30 min, and the solid inorganic material was filtered off through a HyFlo SuperCel bed.
- Step-2 tert-Butyl 3a,4,7,7a-Tetrahydro-lH-isoindole-2(3H)-carboxylate
- the reaction mixture was concentrated under reduced pressure to remove THF and dried under vacuum.
- the n-Hexane (25 ml) and additional water (8 ml) were added and stirred at room temperature for 15 min.
- the reaction mixture was filtered through HyFlo SuperCel, and the layers were separated.
- the aqueous layer was extracted with n-hexane (2 x 20 ml), and the combined organic layer as washed with water (2 x 20 ml) and brine (20 ml).
- the hexane layer was stirred with activated charcoal ( ⁇ 500 mg), for 20min at room temperature, and filtered through HyFlo SuperCel.
- Step-3 2,2-(l -(tert-Butoxycarbonyl)pyrrolidine-3,4-diyl)diacetic Acid
- the reaction mixture was filtered through HyFlo SuperCel, and the residual solid was slurry washed with water (2 x 8 ml).
- the combined filtrate was washed with ethyl acetate (12ml), and the organic layer was separated.
- the aqueous layer was acidified with a 1 N HC1 solution (pH ⁇ 3) and extracted with ethyl acetate (3 x 40 ml).
- the combined ethyl acetate layer was washed with brine (28 ml), treated with activated charcoal (9g), and filtered through the HyFlo SuperCel.
- the organic solvent was distilled under vacuum to afford the title compound (7g) as an off- white solid, which was purified by solvent treatment.
- the reaction mixture was cooled up to 5-10 °C, and MeOH (10 ml) was added dropwise; while the internal temperature was maintained between 10 and 15 °C, addition of methanol was completed within 2 h, and the reaction mixture was cooled up to -5 °C.
- the reaction mixture was poured into 10 ml ice water, and slowly solid sodium carbonate ( ⁇ 12 g, pH ⁇ 10) was added, followed by cyclohexane addition ( ⁇ 50 ml).
- the reaction mixture was stirred for 15 min and filtered through HyFlo SuperCel to remove solid inorganic waste, and the organic layer was separated from the aqueous layer.
- the aqueous layer was extracted with cyclohexane (2 x 40 ml).
- the combined organic solvent was dried over sodium sulfate and concentrated in vacuo.
- Step 1 methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
- Step-2 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
- Step 1 Synthesis of methyl 2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
- Example 1 Title compound was synthesized as per procedure given in step 9 Example 1 by using 3 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (100 mg, 0.147 mmol), K2CO3 (102 mg, 0.736 mmol) and methyl 2-(chloromethyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (43.4 mg, 0.147 mmol) to obtained methyl 2-((2-(6-((4- cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-(oxetan-3-ylmethyl)-
- CHO-hGLP-lR stably expressing full length human GLP-1R
- 50,000 cells/well were seeded in 96 well cell culture plate.
- seeding media was completely aspirated and cells were primed with (100 pl/well) plain media (without FBS) containing 0.1% BSA, 100 pM and 3 pM BETP (2-(Ethylsulfinyl)-4-[3- (phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine) for 30 mins in humidified CO2 incubator.
- BETP (2-(Ethylsulfinyl)-4-[3- (phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine
- lysate was centrifuged for 10 min at 4000 rpm at RT. Finally, 10 pl of lysate was used for cAMP measurement using cAMP Gs dynamic kit (Cis Bio, cat no: 62AM4PEB) according to the manufacturer’s protocol. % cAMP stimulation was measured with respect to the vehicle containing 0.4% DMSO.
- compound of formula (I) of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
- the compounds of formula (I) or pharmaceutical compositions containing them are suitable for humans and other warm blooded animals, and may be administered either by oral, topical or parenteral administration for the treatment of various disease conditions as described hereinbefore.
- composition is provided by employing conventional techniques.
- composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula (I) according to this invention.
- the quantity of active component that is, the compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
- a pharmaceutical composition comprising the compounds of the present invention may comprise a suitable binder, suitable bulking agent &/or diluent and any other suitable agents as may be necessary.
- the pharmaceutical composition may be suitably coated with suitable coating agents. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Abstract
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.
Description
HETEROBIC YCLIC COMPOUNDS AS ORAL GLP1R AGONISTS
FIELD OF INVENTION
The present invention provides novel heterobicyclic compounds of general formula (I) and their salts that are useful for the treatment of diabetes mellitus, obesity and other metabolic disorders especially involving the agonism of the GLP1 receptor. Further, the present invention relates to processes of preparing such compounds, their novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
Formula I
BACKGROUND OF THE INVENTION
Glucagon Like Peptide 1 (GLP1) (7-36) is an endocrine hormone secreted by L cells of pancreas by the stimulation of food intake and other conditions. GLP1 peptide acts as an agonist to stimulate its receptor, GLP1R, to produce insulin and to inhibit glucagon production in a glucose dependent manner.
GLP1R agonism has multiple physiological effects including gastric emptying, satiety, food intake, body weight loss etc. Because of these properties, GLP1R agonists like Exenatide, Liraglutide, and Semaglutide etc. are extensively used for the treatment of diabetes and obesity.
Diabetes and Obesity are the two most common metabolic disorder diseases prevalent in modern lifestyle which are rapidly growing in all parts of the world. Diabetes is associated with hyperglycemia which further causes and becomes responsible for multiple diseases like diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic wound, hypertension, dyslipidemia, hyperinsulinemia etc. Obesity on the other hand is associated with insulin resistance, liver diseases (NAFLD, NASH) etc.
Many GLP1R agonists have been disclosed in the literature - J. Med. Chem. 2022, Nature Medicine 2021, W02020103815, W02022031994, WO2021191812, WO2021118906, WO2021116874 and WO2020234726.
We herein disclose novel compounds of general formula (I) which are oral GLP-1 agonist and are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.
SUMMARY OF THE INVENTION
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.
EMBODIMENT(S) OF THE PRESENT INVENTION
The main objective of the invention is to provide novel compounds of formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical composition comprising them or mixture thereof.
The another embodiment of the invention is to provide a process for the preparation of compound of formula (I), process of their novel intermediates, their pharmaceutically acceptable.
The further embodiment of the present invention is to provide the pharmaceutical compositions containing compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, in combination with suitable pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
The yet another embodiment is to provide the use of the novel compounds of the present invention as anti-metabolic disorder agents, by administering a therapeutically effective & non-toxic amount of the compound as defined by the general formula (I), their
tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical composition comprising them or mixture thereof .
In some embodiments, the compound of formula (I) can be administered in combination with other therapeutic agents. DETAILED DESCRIPTION OF THE INVENTION
Formula (I)
Wherein.
X represent N, CH or -CF;
Y represents hydrogen, halogen, -CN, alkyl and haloalkyl; m represents 1 , 2, 3 and 4.
In another preferred embodiment, the groups referred to above may comprise of:
"Alkyl" by itself or as part of another substituent, means, unless otherwise stated, a straight- or branched- chain, fully saturated aliphatic hydrocarbon radical having the number of carbon atoms designated. For example, "Ci-ealkyl" refers to a hydrocarbon radical, either straight- or branched-chain, that contains from 1 to 6 carbon atoms and that is derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Alkyl includes branched-chain isomers of straight- chain alkyl groups, such as isopropyl, t-butyl, isobutyl, sec-butyl, and the like.
"Halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl", are meant to include an alkyl in which one or more hydrogen is replaced by halogen atoms that can be the same or different, in a number ranging from one up to the maximum number of halogens permitted e.g. for alkyl, (2m'+l), where m' is the total number of carbon atoms in the alkyl group. For example, the term "haloCi-galkyl" is meant to include difluoromethyl, trifluoromethyl, 2,2,2- trifluoroethyl, 4-chlorobutyl, 3 -bromopropyl, and the like. Additionally, term "haloalkoxy" refers to an alkoxy radical substituted with one or more halogen atoms. In one group of embodiments, the haloalkyl and haloalkoxy groups have from one to five or from one to three halogen atoms. Examples of haloalkoxy groups include difluoro methoxy and trifluoro methoxy.
The term "substituted," as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. The term "substituted," as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single tablet/capsule having a fixed
ratio of active ingredients or in multiple, separate tablet/capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
The term "therapeutically acceptable" refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
As used herein, reference to "treatment" of a patient is intended to include prophylaxis. The term "patient" means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the patient is a human.
Compounds of formula (I) may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of formula (I), either as single species or mixtures thereof.
Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula (I).
List of Abbreviation
ACN: acetonitrile
THF: Tetrahydro furan
PSI: pound-force per square inch
DMF: Dimethyl formamide
MTBE: Methyl tert-butyl ether
DCM: Dichloromethane
DIPEA: Disopropyl ethyl amine
EtOAc: Ethyl acetate
K2CO3: Potassium Carbonate
NaHCO: Sodium bicarbonate hrs: Hour(s) rt : room temperature min: Minute(s) tRet: Retention time
HBr: Hydrobromic acid
RT: Room temperature [25-30 °C]
T1D: Type 1 Diabetes
T2DM: Type 2 Diabetes Mellitus
LADA: Latent Autoimmune Diabetes of Adults
EOD: Early Onset type 2 Diabetes
YOAD: Youth-Onset Atypical Diabetes
MODY: Maturity Onset Diabetes of The Young
NAFLD: Non-Alcoholic Fatty Liver Disease
NASH: Nonalcoholic Steatohepatitis
Instrument details
Mass spectrum was recorded on LC-MS 2010-A Shimadzu.
HPLC purity was determined by using Agilent 1100 instrument.
HPLC Column: YMC J Sphere Cl 8 (150X4.6 mm)4p Mobile phase: 0.05 % TFA in water: ACN gradient.
Flow rate: l.O mL/min.
Wave length: UV at 220 nm.
UPLC was determined on Acquity Ultra performance instrument.
UPLC Column: BEHC18 (2.1xl00mm)1.7 p
Mobile phase: 0.05 % TFA in water: ACN gradient.
Flow rate: 0.04 mL/min
NMR spectrum: Bruker Avanc 400 MHz
Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
(S)-2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((3-methoxyoxetan-3- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H- imidazo[4,5-b]pyridine-5-carboxylic acid;
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l -((1 -ethyl- IH-imi dazol-5-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo-imidazole-6- carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5- carboxylic acid;
(2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid compound with 2,2,2-trifluoroacetic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyrazin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid.
Pharmaceutical composition comprising compound of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
Use of the general formula (I) for the treatment of diseases selected from T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson’s Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, and addiction by administering a therapeutically effective & non-toxic amount of the compound of formula (I), or their pharmaceutically acceptable compositions to the mammals.
In one of the embodiments compound of formula (I) of the present invention may be used in combination with one or more suitable pharmaceutically active agents selected from following therapeutic agents in any combination. Compound of formula (I) may appropriately combined with FXR agonist and semi-synthetic bile acid analogue, ACC inhibitor, Dual CCR2 and CCR5 antagonist, Thyroid hormone receptor beta agonist, MAPK5/ ASK-1 inhibitor, SGLT-2 inhibitor, Glucagon-like peptide-1 (GLP-1) receptor agonist, Glucagon-like peptide-1 (GLP-1) mimetics, PPAR a/5 agonist, Stearoyl Coenzyme A Desaturase 1 (SCD1) inhibition-Synthetic fatty acid-bile acid conjugate,
Caspase inhibitor, metformin, sulfonyl ureas, long chain fatty acid agonists (GPR40, GPR120), DPP4 inhibitors, insulin sensitizer, Bempedoic acid or pharmaceutically acceptable salts thereof.
The compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis or variation thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to those described below, where all symbols are as defined earlier.
Synthetic procedures:
General synthetic schematic route for the synthesis of final molecules.
In the general scheme of synthesis of our examples in the invention, an intermediate like amine A was synthetized by multiple steps and similarly a chloro intermediate like B was also synthetized through multiple steps from commercially available starting material. The two intermediates A and B were then coupled in presence of an inorganic base like potassium carbonate to produce precursor compound C. The ester precursor C is then hydrolyzed in the presence of mild base DBU to provide final molecule D which was then purified and tested in different biological assays.
The pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (I) with suitable acids in suitable solvents by processes known in the art.
The invention is further exemplified by the following examples below, which provides some of the several preferred embodiments of the present invention. These examples are
provided merely as representative embodiments and should not be construed to limit the scope of the invention in any way.
Synthetic schemes:
Intermediate 1
Sysnthesis of methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate nzyloxy)methyl)oxetane
Trimethylsulfoxonium iodide (2.68 g, 12.18 mmol) was dissolved in n-butanol (20 ml) and potassium tert-butoxide (1.367 g, 12.18 mmol) was added to it and stirred at 60 °C for 2 hrs. Then, (S)-2-((benzyloxy)methyl)oxirane (1g, 6.09 mmol) was added slowly for a period of 2 min. and stirred at 80 °C for 4 hrs. After completion of reaction solvent was evaporated and crude material was extracted with ethyl acetate. Organic layer was dried over sodium sulfate and evaporated. Crude material was purified by combi flash to obtain ((S)-2-((benzyloxy)methyl)oxetane (0.85 g, 4.77 mmol, 78 % yield).
Step 2:
Compound (S)-2-((benzyloxy)methyl)oxetane (3.9 g, 21.88 mmol) was dissolved in THF (28 ml) and catalytic amount of acetic acid (0.013 ml, 0.219 mmol) was added to it and degassed with nitrogen for 10 min. Then, palladium hydroxide on carbon (0.384 g, 0.547 mmol) was added to it and reaction was kept in autoclave at 50 °C under 80 PSI hydrogen pressure for 6 hrs and further at RT for 14 hrs. Next day reaction was continued at 70 °C for 6 hrs. After completion of reaction, reaction mass was filtered through celite
and crude material (in THF solution) was directly used for next step considering 100% yield.
Step 3:
THF solution (20 mL) of (S)-oxetan-2-ylmethanol (0.47 g, 5.33 mmol) was cooled to 0 °C and triethylamine (1.859 ml, 13.34 mmol) was added to it and stirred for 10 min. Then, methanesulfonic anhydride (1.394 g, 8.00 mmol) was added to it maintaining temperature 0-10 °C. Further, reaction mixture was stirred for overnight. Then, ice water was added to the reaction and extracted with ethyl acetate. Organic layer was washed with water, brine and dried over sodium sulfate. Crude material was purified by combiflash to obtain (S)-oxetan-2-ylmethyl methanesulfonate (600 mg, 3.61 mmol, 67.7 % yield).
Step 4:
Compound (S)-oxetan-2-ylmethyl methanesulfonate (600 mg, 3.61 mmol) was dissolved in N,N-Dimethylformamide (12 ml) and sodium azide (352 mg, 5.42 mmol) was added to it and reaction mixture was heated to 80 °C for 3 hrs. After completion of reaction, reaction mixture was cooled and diethyl ether was added and filtered through celite. Crude material was evaporated and directly used for next step.
Step 5:
Solution of Compound (S)-2-(azidomethyl)oxetane (408 mg, 3.61 mmol) in DMF (3 mL) was dissolved in THF (8 ml) and degassed by nitrogen for 5 min. Then, palladium on charcoal (384 mg, 3.61 mmol) was added and reaction mixture was stirred under
hydrogen at 55 PSI for overnight (16 hrs) at RT. After completion of reaction, reaction mixture was passed through celite and solution was directly used for next step considering 100% yield.
Step 6:
Solution of (S)-oxetan-2-ylmethanamine (314 mg, 3.60 mmol) was dissolved in THF (20 ml) and methyl 3-fluoro-4-nitrobenzoate (718 mg, 3.60 mmol), triethylamine( 1.507 ml, 10.81 mmol) was added to it and reaction mixture was heated at 40 °C overnight. After completion of reaction, solvent was evaporated and crude material was extracted with ethyl acetate. Organic layer was washed with water, brine and dried over sodium sulphate. Crude material obtained was purified by combi flash to obtain methyl (S)-4- nitro-3-((oxetan-2-ylmethyl)amino)benzoate (250 mg, 0.939 mmol, 26.1 % yield).
Step 7:
Solution of Compound methyl (S)-4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate (250 mg, 0.939 mmol) was dissolved in MeOH (8 ml) and degassed by nitrogen for 5 min. Then, palladium on charcoal (24.98 mg, 0.023 mmol) was added and reaction mixture was stirred under hydrogen at 55 PSI for overnight (16 hrs) at room temperature. After completion of reaction, reaction mixture was passed through celite and solution was directly used for next step.
Step 8:
Preparation of methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (210 mg, 0.889 mmol) and 2- chl oro-1, 1,1 -trimethoxy ethane (151 mg, 0.978 mmol) was dissolved in Acetonitrile (5 ml) and catalytic amount of p- toluenesulfonic acid monohydrate (8.45 mg, 0.044 mmol) was added to it and reaction mixture was heated to 60 °C for 2 hrs. The reaction mixture was heated overnight. After completion of reaction, solvent was evaporated and crude material was purified by combi flash to obtain methyl (S)-2-(chloromethyl)-l-(oxetan-2- ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (160 mg, 0.543 mmol, 61.1 % yield).
Example 01
(S)-2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Synthesis of intermediate tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)- carboxylate 4-methylbenzenesulfonate
Step 1:
Preparation of l,4-dibromo-2,3-bis(bromomethyl)but-2-ene
Take the 2,3 -dimethylbutane (15.11 ml, 116 mmol) in RBF, put the flask in cooling bath by maintain temp. 0-5°C and then add bromine (46.3 ml, 899 mmol) in it and then add HBr (1.313 ml, 11.60 mmol) and reflux the reaction mixture up to 42-45°C for 20 hr. Add the aqueous solution of sodium bisulphate in reaction mix and then dilute it with ethyl acetate and spot the organic layer. Add water to the reaction mixture Ice cool water and add aqueous solution of NaHSO3 in reaction to quench excess bromine (till the colour of reaction mix. become colourless), decant the water layer from sticky yellow solid. Add MTBE in it and stir it for half an hour and then free flow yellow solid observed and filter it and dry it. Take crude bromo, and add ethyl acetate in it and reflux it for 30 min and cool it 5-10°C stir for 30 min again and filter the solution and dry it. l,4-Dibromo-2,3-bis(bromomethyl)but-2-ene was obtained. (5.66 g, 14.16 mmol, 12.20 % yield).
Take the l,4-dibromo-2,3-bis(bromomethyl)but-2-ene (1 g, 2.502 mmol) in flask and DMF (13.00 ml) in it then add K2CO3 (5.59 g, 40.4 mmol) in it at room temperature and then add /?-Toluenesulfonamide (1.000 g, 5.84 mmol) in it let it stir at room temperature for 16hr. Add ice in reaction mixture and stir it for 10 min and free flow solid precipitate out filter it and dry it. (820 mg, 78% Yield).
Step 3:
Preparation of l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole dihydrobromide
HBr HN i NH HBr
Take the 2,5-ditosyl-l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole (1.0 g, 2.389 mmol) in RBF, put the RBF in cooling bath 0°C and then HBr (5.52 ml, 47.8 mmol) was added in it and then phenol (1.010 ml, 10.08 mmol) was added(hot liquid) in it and let it stir and heat it up to 110°C for 16hrs. Let the reaction mixture cool and then add hyflow in it and hyflow filter it, wash it with hydrobromic acid and with DCM. Separate the layer and wash the aqueous layer with DCM (3 times). Add charcoal in aqueous layer and stir it for
15 min., hyflow filter it and wash with hydrobromic acid. Concentrate the hydrobromic acid layer below 60°C. Dry it completely and wash with (1 :1) ethanol:DIPE, stir it for half an hour and filter it. Wash the solid with (1 :1) ethanol:DIPE , dry the solid. (330 mg, 50.8% yield).
Step 4:
In 25 ml RBF, charge potable water (3 ml) and sodium bicarbonate (273 mg, 3.25 mmol) at 25-35 °C, cool it to 20 °C. l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole dihydrobromide (295 mg, 1.08 mmol) was added portion wise at 20-25 °C. Boc Anhydride (0.55 ml) in MeOH (0.6 ml) was added in to it at 25-30°C. Stirred it for 16 hrs. Filter the solid and wash with water to obtain di-tert-butyl 4,6-dihydropyrrolo[3,4-c]pyrrole-2,5(lH,3H)- dicarboxylate (274 mg, 81% yield) Step 5:
Preparation of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate 4- methylbenzenesulfonate
In 25 ml RBF, charge di-tert-butyl 4,6-dihydropyrrolo[3,4-c]pyrrole-2,5(lH,3H)- dicarboxylate (274 mg, 0.883 mmol) in isopropyl acetate (8.22 ml) p-toluenesulfonic acid (168 mg, 0.883 mmol) was added at 25°C and stirred it for 16 hrs. Filter the solid and wash with isopropyl acetate to 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate 4-methylbenzenesulfonate (212 mg, 62.8% yield).
Step 6:
Preparation of tert-butyl 5-(6-chloropyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole- 2(1 H)-carboxylate
To a solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate 4- methylbenzenesulfonate (4.3 g, 11.24 mmol) and 2,6-dichloro pyridine (1.66 g, 11.24 mmol) in dimethylformamide (20 ml) was placed caesium carbonate (9.16 g, 28.1 mmol). The reaction mixture was stirred at 80°C for 16 hrs, Reaction mixture was quenched by adding reaction mixture to water. Product was extracted using ethyl acetate, washed with water, brine, dried over sodium sulphate, concentrate and purified by column chromatography to obtain tert-butyl 5-(6-chloropyridin-2-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (1.6 g, 44 % yield).
Step 7:
Preparation of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate
To a clear solution of tert-butyl 5-(6-chloropyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrole-2(lH)-carboxylate (0.3 g, 0.93 mmol) in toluene (6 ml). Degassed it with N2 balloon. 3-fluoro-4-(hydroxymethyl)benzonitrile (211 mg, 1.39 mmol), CS2CO3 (759 mg, 2.33 mmol), Johnphos (34.8 mg, 0.11 mmol) and Pd2(dba)s (53.8 mg, 0.059 mmol) was added in to it at 25°C. Again degassed it. Reaction mass was stirred at preheated 110- 120°C for 3 hrs. Product was diluted with ethyl acetate (15 ml) and fdter the solid. Evaporate the solvent under reduced pressure and product was purified by column chromatography to obtain tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)- 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (170 mg, 41.8 % yield).
Step 8
Preparation of 3-fluoro-4-(((6-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyridin- 2-yl)oxy)methyl)benzonitrile 4-methylbenzenesulfonate
To a solution of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (170 mg, 0.38 mmol) in EtOAc (3.4 ml) /?-toluenesulfonic acid monohydrate (200 mg, 1.05 mmol) was added at 25°C. The reaction mixture was stirred at 60°C for 2 hrs, Filter the solid to obtain 3-fluoro-4-(((6- (3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyridin-2-yl)oxy)methyl)benzonitrile 4- methylbenzenesulfonate (179 mg, 67.5 % yield).
Step-9
Methyl(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
3-fluoro-4-(((6-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyridin-2- yl)oxy)methyl)benzonitrile 4-methylbenzenesulfonate (90 mg, 0.132 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (39mg, 0.132 mmol) was dissolved in Acetonitrile (2 ml) and potassium carbonate (91 mg, 0.66 mmol) was added to it and reaction mixture was heated to 60 °C was heated for 2hrs. After completion of reaction, After completion of reaction, Dilute RM with EtOAc and wash with water and brine, evaporate the solvent and crude material was purified by combi flash to obtain methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-
3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate (40 mg, 50.9 % yield). Mass [M+H]+ = 595.3 Step- 10
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Compound methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (40 mg, 0.067 mmol) was dissolved in ACN (1 ml) Then l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (19.48 mg, 0.14 mmol) in water (0.2 ml) was added and reaction mixture was stirred at RT for overnight (16 h) After completion of reaction, evaporate the solvent and dilute it with water. Reaction mixture was acidify with 10% citric acid solution. Extract the product with EtOAc (10 ml), wash with H2O (5 ml), brine (5 ml), dried over Na2SO4 and concentrate. Purified the product through combiflash to obtain (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin- 2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid ( 10 mg, 25.6% yield). Mass [M+H]+ = 581.2 'H-NMR (400 MHz, DMSO-d6) 5 12.8(bs, 1H), 8.26 (s, 1H), 7.80-7.88 (m, 2H), 7.64- 7.69 (m, 3H), 7.43-7.47 (m, 1H), 6.06 (d, J=8.0Hz, 1H), 5.96 (d, J= 8.0 Hz, 1H), 5.44 (s, 2H), 5.1 (m, 1H), 4.7-4.9 (m, 3H), 4.24-4.37 (m, 3H), 4.08 (m, 4H), 3.6 (m, 4H), 2.33- 2.43(m, 2H)
Example 02
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step-1 methyl2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 1 using 3-fluoro-4-(((6-(3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyridin-2-yl)oxy)methyl)benzonitrile 4- methylbenzenesulfonate and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)- l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (40mg,77 % yield).
Step-2
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Procedure same as written in step 10 in Example 1 using methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-
1-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2-((5-(6-((2-fluoro-4- isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid (10 mg, 21.34 % yield). Mass [M+H]+ = 569.1 Example 03
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2( 1 H)-yl)methyl)- 1 -((3 -methoxy oxetan-3 -yl)methyl)- 1 H-benzo[d] imidazole-6- carboxylic acid
Step-1
Methyl 2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2( lH)-yl)methyl)- 1 -((3 -methoxy oxetan-3-yl)methyl)- 1 H- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 1 using 3-fluoro-4-(((6-(3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyridin-2-yl)oxy)methyl)benzonitrile 4- methylbenzenesulfonate and methyl 2-(chloromethyl)-l -((3 -methoxy ox etan-3 - yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((2-fluoro-4- isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (33 mg, 29.9 % yield).
Step-2
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2( 1 H)-yl)methyl)- 1 -((3 -methoxy oxetan-3 -yl)methyl)- 1 H-benzo[d] imidazole-6- carboxylic acid
Procedure same as written in step 10 in Example 1 using methyl 2-((5-(6-((2-fluoro-4- isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)- 1 -((3 -methoxyoxetan-3 -yl)methyl)- 1 H-benzo[d] imidazole-6-carboxylate to obtain2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2( lH)-yl)methyl)- 1 -((3 -methoxy oxetan-3-yl)methyl)- 1 H- benzo[d]imidazole-6-carboxylic acid(8 mg, 20.90 % yield). Mass [M+H]+ = 611.5
'H-NMR (400 MHz, DMSO-d6) 5 8.51 (s, 1H),7.9-8.O (m, 2H), 7.6-7.8 (m, 3H), 7.52(m, 1H), 6.13 (d, J=8.0Hz, 1H), 6.00 (d, J= 8.0 Hz, 1H), 5.46 (s, 2H), 5.1 (s, 2H), 4.92 (s, 2H), 4.76 (s, 3H), 4.52 (m, 4H), 4.38 (m, 4H), 4.17(m, 4H)
Example 04 (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step: 1
Preparation of 2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-l , 2, 3, 4,5,6- hexahydropyrrolo[3,4-c]pyrrole bis(4-methylbenzenesulfonate)
Procedure same as written in step 8 in Example 1 using tert-butyl 5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)- carboxylate to obtain 2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,4,5,6- hexahydropyrrolo[3,4-c]pyrrole bis(4-methylbenzenesulfonate)
(150mg, 61.7 % yield). Mass [M+H]+ = 346.1
Step-2
methyl(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3 ,4-c]pyrrol-2(l H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1H- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 1 using 2-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole bis(4- methylbenzenesulfonate)and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl(S)-2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)- l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate(74 mg, 53.9 % yield). Mass [M+H]+ = 604.3
Step-3
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Procedure same as written in step 10 in Example 1 using methyl(S)-2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)- l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate to obtain (S)-2-((5-(6-((4- chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylicacid ( 6mg, 6.49 % yield). Mass [M+H]+ = 590.4
'H-NMR (400 MHz, DMSO-d6) 5 8.37 (s, 1H), 7.9-7.92 (m, 1H), 7.77-7.79 (m, 1H), 7.4- 7.6(m, 3H), 7.3-7.4 (m, 1H), 6.00-6.10 (m, 2H), 5.36 (s, 2H), 5.1-5.3 (m, 3H), 4.64 (m, 2H), 4.36-4.39 (m, 4H), 4.21 (m, 4H), 2.7-2.8 (m, 2H), 2.2-2.3(m, 2H)
Example 05
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step-1 methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 1 using 2-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole bis(4- methylbenzenesulfonate)and methyl 2-(chloromethyl)-l -(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)- l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (54 mg, 40% yield). Mass [M+H]+ = 593.4
Step-2
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate (54 mg, 0.091 mmol) was dissolved in MeOH (1.1 ml). Then Lithium Hydroxide monohydrate (19.10 mg, 0.455 mmol) in Water (0.25 ml) was added and reaction mixture was stirred at RT for overnight (16 h) After completion of reaction, evaporate the solvent and dilute it with water. Reaction mixture was acidify with 10% citric acid soln. Filter the solid compound. Purified the Product to obtain desire product. (5 mg, 7.41 % yield). Mass [M+H]+ = 579.4
'H-NMR (400 MHz, DMSO-d6) 5 8.26-8.28 (m, 1H), 8.07-8.09 (m, 1H), 7.46-7.61 (m, 4H), 7.30-7.32(m, 1H), 6.09 (d, J=8.0Hz, 1H), 6.00 (d, J=8.0Hz, 1H), 5.36 (s, 2H), 4.57- 4.58 (m, 3H), 4.21 (m, 5H), 3.71-3.74 (m, 3H), 3.21-3.26 (m, 6H)
Example 06
(S)-2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1
Preparation of 3 -fluoro-4-(((2-(3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)- yl)pyrimidin-4-yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulfonate)
To a solution of tert-butyl 5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (155 mg, 0.35 mmol) in EtOAc (3.1 ml) para toluene sulfonic acid monohydrate (182 mg, 0.95 mmol) was added at 25°C. The reaction mixture was stirred at 60°C for 2 hrs, Filter the solid to obtain 3-fluoro-4- (((2-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyrimidin-4- yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulfonate) (242 mg, 100 % yield).
Step-2 methyl (S)-2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 1 using 3-fluoro-4-(((2-(3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyrimidin-4-yl)oxy)methyl)benzonitrile bis(4- methylbenzenesulfonate) to obtain methyl (S)-2-((5-(4-((4-cyano-2- fluorobenzyl)oxy)pyrimidin-2-yl)-3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-
yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate ( 52 mg, 24.59
% yield). Mass [M+H]+ = 596.4
Step-3
(S)-2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Procedure same as written in step 10 in Example 1 using methyl (S)-2-((5-(4-((4-cyano- 2-fluorobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate to obtain (S)-2- ((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid ( 5 mg, 8.80 % yield). Mass [M+H]+ = 582.4
'H-NMR (400 MHz, DMSO-d6) 5 12.90(bs, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 7.87-7.92 (m, 2H), 7.72-7.76(m, 3H), 6.22 (d, J=5.6Hz, 1H), 5.51 (s, 2H), 4.75-4.81 (m, 1H), 4.62- 4.79 (m, 3H), 4.32-4.37 (m, 2H), 4.11-4.25 (m, 7H), 2.61-2.73(m, 2H), 2.37-2.42(m, 2H)
Example 07
(S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step-1 methyl (S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
To a solution 3-fluoro-4-(((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)pyrimidin- 2-yl)oxy)methyl)benzonitrile 4-methylbenzenesulfonate (90 mg, 0.177 mmol) in acetonitrile (1 ml) were added potassium carbonate (122 mg, 0.833 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (90 mg, 0.177 mmol) and reaction mixture was stirred at 60-70 °C for 2 hrs. Reaction mixture was cooled to rt charged water and extracted with ethyl acetate. Adsorbed on silica and eluted with 0 to 80 % ethyl acetate in hexane to obtained methyl (S)-2-((5-(2-((4-cyano- 2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l -(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (50mg, yield 38%) Mass m/z 596.4 [M+H]+ Step-2
Synthesis of (S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
To a solution of methyl (S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-5-carboxylate (50 mg, 0.084 mmol) in acetonitrile (1 ml) was added
aqueous solution of l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (24.31 mg, 0.175 mmol) and reaction mixture was stirred at RT for 20 hrs. Removed organic solvent and acidify with 10% citric acid sol. to pH 5 to 6. Precipitated solid was filtered and dried. Stirred solid in diethyl ether and filtered to obtained (S)-2-((5-(2-((4-cyano-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)- yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid (4 mg, yield 7%) Mass m/z 582.4 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.6O(1H, s), 8.29(1H, dd, J=10.3Hz& J=2.3Hz), 8.17(1H, dd, J=7.2&J=1.6Hz), 8.02(lH, d, J=8.2Hz), 7.99(1H, s), 7.39(1H, d, 8.2Hz), 7.31(1H, dd, J=8.2Hz& J=2.2Hz), 6.3O(1H, m), 5.31(2H, s), 4.98(2H, m), 4.57(2H,m), 4.55(2H,s), 3.81(2H, s), 3.88(4H, m), 3.11(4H, m), 2.5(1H, m)
Example 08
2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Synthesis of methyl 2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3 ,4-c]pyrrol-2(l H)-yl)methyl)- 1 -(2-methoxy ethyl)- 1H- benzo[d]imidazole-6-carboxylate
Title compound was synthesized using methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate (36.1 mg, 0.128 mmol)and potassium carbonate (88
mg, 0.638 mmol), 3-fluoro-4-(((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)pyrimidin-2-yl)oxy)methyl)benzonitrile 4-methylbenzenesulfonate (65 mg, 0.128 mmol) to obtained methyl 2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(2-methoxyethyl)- 1 H- benzo[d]imidazole-6-carboxylate (22 mg, yield 30 %) Mass m/z 584.4 [M+H]+ Step-2
Synthesis of 2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 Example 1 by using methyl2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate (0.022 g, 0.038 mmol)and l,3,4,6,7,8-hexahydro-2H- pyrimido[l,2-a]pyrimidine (10.91 mg, 0.078 mmol) to obtained 2-((5-(2-((4-cyano-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid (4 mg, yield 30%) Mass m/z 570.4[M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.51(1H, s), 8.31(1H, dd, J=12.4Hz& J=2.9Hz), 8.11(1H, dd, 6Hz), 7.91(1H, d, J=7.5Hz), 7.97(1H, s), 7.35(1H, d, 9Hz), 7.35(1H, dd, J=11.2Hz& J=2.2Hz), 6.3O(1H, s), 5.36(2H, s), 4.91(2H, s), 4.33(2H, t, 7.2Hz), 3.90(2H, m), 3.89(4H, m), 3.31(3H, s), 3.09(4H, m)
Example 09
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid
Step- 1
Preparation of tert-butyl 5-(2-(chloropyrimidine-4-yl)-3,4,5,6-tetrahydropyrrolo-2 [3,4-c] pyrrole-2- (1H)- carboxylate
To a solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate 4- methylbenzenesulfonate (2.57 gm, 6.71 mmol) and 2,4-dichloro pyrimidine (1 gm, 6.71 mmol) in dimethylformamide (20 ml) was placed triethyl amine (4.68 ml). The reaction mixture was stirred at 25°C for 16 hrs, Reaction mixture was quenched by adding reaction mixture to water. Product was extracted using ethyl acetate, washed with water, brine, dried over sodium sulphate, concentrate and purified by column chromatography to obtain tert-butyl 5-(2-(chloropyrimidine-4-yl)-3,4,5,6-tetrahydropyrrolo-2 [3,4-c] pyrrole- 2- (1H)- carboxylate (850 mg, 39.2 % yield). Mass m/z [M+H]+ = 323.2
Step- 2 Synthesis of tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate
Tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate was synthesized using tert-butyl 5-(2- chloropyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (400 mg, 1.239 mmol) in toluene (4 ml). Degassed it with N2 balloon. (4-chloro-2- fluorophenyl)methanol (398 mg, 2.478 mmol), CS2CO3 (1.0 gm, 3.10 mmol), BINAP (116 mg, 0.186 mmole combiflash) and Pd2(dba)3, (68.1 mg, 0.074 mmol) was added in to it at 25 °C. Again degassed it. Reaction mass was stirred at preheated 110-120°C for 16 hrs. Product was diluted with ethyl acetate (15 ml) and filter the solid. Evaporate the solvent under reduced pressure and product was purified by column chromatography to obtain tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (480 mg, 87 % yield). Mass m/z [M+H]+ = 447.3
Step- 3
Synthesis of 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6- hexahydropyrrolo[3,4-c]pyrrole bis(4-methylbenzenesulfonate)
Title compound was synthesized using procedure given in step 8 of previous example 1 using tert-butyl 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrole-2(lH)-carboxylate (200 mg, 0.448 mmol) to obtain 2-(2- ((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4- c]pyrrole bis(4-methylbenzenesulfonate) (250 mg, 81%yield). Mass m/z [M+H]+ = 347.2
Step- 4
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylate
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylate was done using procedure given in step 9 in previous examplel using 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6- hexahydropyrrolo[3,4-c]pyrrole bis(4-methylbenzenesulfonate) (50 mg, 0.096 mmol) and methyl 2-(chloromethyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (27.32 mg, 0.096 mmol) with K2CO3 (66.6 mg, 0.482 mmol) methyl 2-((5-(2-((4-chloro- 2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (35 mg, 61%) mass m/z[M+H]+ = 594.3
Step- 5
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylic acid
To a solution of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylate (35 mg, 0.059 mmol) in methanol (2 ml) was added aqueous solution of LiOH (10 mg, 0.236 mmol) at room temperature and stirred for 20 hrs. After
completion of reaction, solvent was removed and charged 10 % citric acid solution till pH 6 to 6.5 and solid was filtered and wash with water and dry to obtain (2-((5-(2-((4-chloro- 2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (3 mg, 9 % yield). Mass m/z [M+H]+ = 580.4
'H-NMR (400 MHz, DMSO-d6) 5 8.34 (d, 1H), 8.29-8.31 (d,lH), 7.81-7.83 (m, 2H), 7.15-7.17 (m, 2H), 7.35-7.37 (m,lH) , 5.16 (s, 2H), 4.65 (s, 4H), .4.48-4.51 (m, 4H), 4.43 (s, 2H,), 3.85 (s,lH), 3.35-3.37 (m, 3H), 3.23 (s, 3H), 3.03(s,lH)
Example 10
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Synthesis of methyl (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 by using 2-(2-((4- chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole (290 mg, 0.836 mmol), K2CO3 (347 mg, 2.53 mmol) and methyl (S)-2-(chloromethyl)-3- (oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (296 mg, 0.836 mmol) to
methyl (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (210 mg, yield 42 %) Mass m/z 606.4 [M+H]+
Step-2
Synthesis of (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 by using methyl (S)-2- ((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (0.19 g, 0.314 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (87 mg, 0.628 mmol) to obtained (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylic acid (130 mg, yield 65 %) Mass m/z 592.4 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) 5 8.4O(1H, s), 8.21(1H, dd, J=11.3Hz& J=3.3Hz), 8.12(1H, dd, J=9.2&J=3.6Hz), 7.97(1H, d, J=7.2Hz), 7.91(1H, s), 7.29(1H, d, 9.9Hz), 7.21(1H, dd, J=8.2Hz& J=2.2Hz), 6.29(1H, m), 5.29(2H, s), 4.91(2H, m), 4.55(2H,m), 4.57(2H,s), 3.87(2H, s), 3.81(4H, m), 3.09(4H, m), 2.5(1H, m)
Example 11
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l -((1 -ethyl- IH-imi dazol-5-yl)methyl)-lH-benzo[d]imi dazole- 6-carboxylic acid
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- 1 H-benzo [d] imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 Example 1 by using 2- (2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4- c]pyrrole (100 mg, 0.126 mmol), K2CO3 (133 mg, 0.631 mmol) and methyl (S)-2- (chloromethyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (60 mg, 0.126 mmol) methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylate(50 mg, yield 9 %) Mass m/z 586.3 [M+H]+
Step2:
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3, 4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
1 H-benzo [d] imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 5 by using methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylate (50 mg, 0.014 mmol) and LiOH.H2O (16 mg, 0.096 mmol) to obtained 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylic acid (10 mg, yield 58 %) Mass m/z 572.2 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) 5 8.30(lH, s), 8.12(1H, dd, J=10.3Hz& J=2.3Hz), 8.01(lH, dd, 5.6Hz), 7.87(1H, d, J=7.2Hz), 7.85(1H, s), 7.31(1H, d, 10Hz), 7.24(1H, dd, J=13.2Hz& J=2.2Hz), 6.25(1H, m), 5.26(2H, s), 4.93(2H, s), 4.33(2H, s), 4.13(2H, m), 3.85(4H, m), 3.09(4H, m), 1.25(3H, t, J=5.2Hz)
Example 12
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH-
Title compound was synthesized as per procedure given in step 9 Example 1 by using 2- (2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,4,5,6-hexahydropyrrolo[3,4- c]pyrrole (100 mg, 0.126 mmol), K2CO3 (133 mg, 0.631 mmol) and methyl 2- (chloromethyl)-l -(thiazol-5-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (64 mg,
0.126 mmol) to obtained methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(thiazol- 5-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate (50 mg, yield 9 %) Mass m/z 586.3 [M+H]+ Step: 2
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 5 by using methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (40 mg, 0.014 mmol) and LiOH.H2O (16 mg, 0.096 mmol) to obtained 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid (3 mg, yield 58 %) Mass m/z 572.2 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) 5 9.2(1H, s), 8.31(1H, s), 8.10(lH, dd, J=11.3Hz& J=3.3Hz), 8.01(lH, dd, 9.6Hz&J=2.3Hz), 7.87(1H, d, J=7.2Hz), 7.81(1H, s), 7.21(1H, d, 9.0Hz), 7.24(1H, dd, J=13.2Hz& J=2.2Hz),7.01(lH, s), 6.2O(1H, m), 5.26(2H, s), 4.93(2H, s), 4.33(2H, s), 3.81(4H, m), 3.09(4H, m)
Example 13
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step-1
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 Example 1 by using methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (lOOmg, 0.193 mmol)and potassium carbonate (133 mg, 0.963 mmol),3-fluoro-4-(((4- (3,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)pyrimidin-2-yl)oxy)methyl)benzonitrile 4-methylbenzenesulfonate (55 mg, 0.193 mmol) to obtained methyl 2-((5-(2-((4-chloro- 2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (40 mg, yield 35%) Mass m/z 593.5 [M+H]+
Step-2
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 5 by using methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate(0.040g,0.067mmol) and l,3,4,6,7,8-hexahydro-2H- pyrimido[l,2-a]pyrimidine (20 mg, 0.140 mmol) to obtained 2,2,2-trifluoroacetic acid compound with 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid (4 mg, yield 9%) Mass m/z 579.5[M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 12.93(lH,bs), 8.31(1H, s), 8.11(1H, dd, J=11.3Hz& J=2.3Hz), 8.02(lH, dd, 5.6Hz), 7.89(1H, d, J=7.2Hz), 7.87(1H, s), 7.3O(1H, d, 11Hz), 7.25(1H, dd, J=14.2Hz& J=4.2Hz), 6.25(1H, m), 5.26(2H, s), 4.93(2H, s), 4.33(2H, t, 6.2Hz), 3.95(2H, m), 3.86(4H, m), 3.35(3H, s), 3.09(4H, m)
Synthesis of Intermediate 02
Step-1
To a cooled solution (0 to 5 °C) of potassium tert-butoxide (15.57 g, 139 mmol) in THF (200 ml) was added mixture of dimethyl fumarate (10 g, 69.4 mmol) and TOSMIC (13.55 g, 69.4 mmol) in THF (100 ml) dropwise by addition funnel in 30 to 45 min. Reaction mixture stirred at same temp for 0.5 hr. Remove ice bath and stirred at RT for 0.5 hr. Reaction mixture dumped in brine solution 20 ml. Extracted with 100 ml ethyl acetate. Combined organic layer dry on sodium sulfate and concentrated. Resulting solid was stirred in ethyl acetate and filtered to obtained dimethyl lH-pyrrole-3,4-dicarboxylate (7 g, yield 52%) Mass m/zl84.1 [M+H]+ Step-2
To a solution of dimethyl lH-pyrrole-3,4-dicarboxylate (7 g, 38.2 mmol) in DMF (70 ml) was added NaH (2.293 g, 57.3 mmol) lot wise under cooling and N2 atm. Reaction mixture was stirred at RT for 15 min, then cooled and 4-methylbenzenesulfonyl chloride (8.74 g, 45.9 mmol) was added lot wise and stirred at RT for 2 hr. Charged ice water and precipitated solid was filtered dry to obtained dimethyl l-tosyl-lH-pyrrole-3,4- dicarboxylate (7 g, yield 54%). Mass m/z 338.1 [M+H]+ Step-3
Synthesis of (1 -tosyl- lH-pyrrole-3,4-diyl)dimethanol
To a solution of dimethyl 1 -tosyl- lH-pyrrole-3,4-dicarboxylate (3.8 g, 11.26 mmol) in THF (65.0 ml) was added lithium aluminum hydride (0.855 g, 22.53 mmol) lot wise under cooling in 30 min. Reaction mixture was stirred for 1 hr at RT. After completion of reaction, quenched with wet sodium sulfate and stirred for 0.5 hr. Filtered solid wash with ethyl acetate concentrated and purified by column with 0 to 60% ethyl acetate in hexane to obtained (l-tosyl-lH-pyrrole-3,4-diyl)dimethanol (1.5 g, yield 47%). Mass m/z 282.1 [M+H]+
Step-4
To a solution of (1 -tosyl- lH-pyrrole-3,4-diyl)dimethanol (1.5 g, 5.33 mmol) in DCM (30 ml) was added phosphorous tribromide (1.006 ml, 10.66 mmol) dropwise under cooling (0-5 °C). After addition, temp slowly raised to 5-10 °C and stirred for 1 hr. Reaction mixture was diluted with sat. sodium bicarbonate and extracted with DCM and purified by column with 0 to 5% ethyl acetate to obtained 3,4-bis(bromomethyl)-l-tosyl-lH- pyrrole (1.0 g, yield 46%).
Step- 5
To a solution of 3,4-bis(bromomethyl)-l-tosyl-lH-pyrrole (700 mg, 1.719 mmol) in DMF (8 ml) were added N-ethyl-N-isopropylpropan-2-amine (0.744 ml, 4.30 mmol) and stir and added triphenylmethanamine (535 mg, 2.063 mmol) and reaction mixture stirred
at 50 C for 2 hr. Charged water and precipitated solid was filtered and suck dry well and load into column and eluted with 0 to 15% ethyl acetate in hexane to obtained 5-tosyl-2- trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (0.5 g , yield 39%).
Step-6
Flask covered by aluminum foil to protect from sunlight and charged 5-tosyl-2-trityl- l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (3.1 g, 6.14 mmol) in DMSO (45 ml), and cooled to 20 °C and added potassium tert-butoxide (2.068 g, 18.43 mmol) lot wise then stir reaction mixture at RT for 5 min. Charged water and precipitated solid was filtered and wash with water and dried to obtained 2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (1.3 g, yield 60%).
Synthesis of Intermediate 03
Synthesis of 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)3 -fluorobenzonitrile bis(2,2,2-trifluoroacetate)
Step-1
To a solution of 2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (800 mg, 2.283 mmol, in DMF (3 ml) was then added sodium hydride (183 mg, 4.57 mmol) at RT and reaction mixture was stirred for 10 min. then added 2,6-dichloropyridine (338 mg, 2.283 mmol) and reaction mixture stirred at 65 °C for 1 to 1.5 hr. Then reaction mixture was cooled to RT and ice was added, precipitated solid was filtered and suck dried to obtained 5-(6- chloropyridin-2-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (855 g, yield 81%). Step-2
Synthesis of 3-fluoro-4-(((6-(5-trityl-5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)benzonitrile
To a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (147 mg, 0.974 mmol), 5-(6- chloropyridin-2-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (300 mg, 0.649 mmol) and Cs2CO3 (529 mg, 1.623 mmol) in Toluene (1.5 ml), N2 was bubbled for 10 min. Added Pd2(dba)3 (59.5 mg, 0.065 mmol) and [l,l'-bi phenyl] -2-yldi-tert- butylphosphane (38.8 mg, 0.130 mmol) and N2 bubbled for further 5 min. and flask kept under stirring on preheated oil bath at temp. 110-120 °C for 3 hrs. Reaction mixture was cooled and adsorbed on silica and eluted with 0 to 5% ethyl acetate in hexane to obtained 3-fluoro-4-(((6-(5-trityl-5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)benzonitrile (200 mg, yield 53%) Step-3
Synthesis of 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)3 -fluorobenzonitrile bis(2,2,2-trifluoroacetate)
To a solution of 3-fhioro-4-(((6-(5-trityl-5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)- yl)pyridin-2-yl)oxy)methyl)benzonitrile (200 mg, 0.347 mmol) in DCM (5 ml) were added TFA (0.401 ml, 5.20 mmol) at RT and reaction mixture was stirred for 0.5 hr at RT. Removed solvent and triturated in diethyl ether to obtained 4-(((6-(5,6- dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile bis(2,2,2-trifluoroacetate) (150 mg, yield 77%), Mass m/z 335.2 [M+H]+
Synthesis of Intermediate 04
5-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-l,2,3,5-tetrahydropyrrolo[3,4- c]pyrrole bis(2,2,2-trifluoroacetate)
Synthesis of 5-(6-((5-chl oropyridin-2-yl)methoxy)pyridin-2-yl)-2-trityl-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole
Title compound was synthesized as per procedure given in step 2 of intermediate 3 by using 5-(6-chloropyridin-2-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole and (5- chloropyridin-2-yl)methanol to obtained 5-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2- yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole
Step 2:
Synthesis of 5-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-l,2,3,5- tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2-trifluoroacetate)
Title compound was synthesized as per procedure given in step 3 of intermediate 3 by using 5-(6-((5-chl oropyridin-2-yl)methoxy)pyridin-2-yl)-2-trityl-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole to obtained 5-(6-((5-chloropyridin-2-yl)methoxy)pyridin- 2-yl)-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2-trifluoroacetate) Mass m/z 327 [M+H]+
Synthesis of Intermediate 05
6-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2-yl)oxy)methyl)nicotinonitrile bis(2,2,2-trifluoroacetate)
Step 1:
Synthesis of 6-(((6-(5-trityl-5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)nicotinonitrile
Title compound was synthesized as per procedure given in step 2 of intermediate 3 by using 5-(6-chloropyridin-2-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole and 6- (hydroxymethyl)nicotinonitrile to obtained 6-(((6-(5-trityl-5,6-dihydropyrrolo[3,4- c]pyrrol-2(4H)-yl)pyridin-2-yl)oxy)methyl)nicotinonitrile Step 2:
Synthesis of 6-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)nicotinonitrile bis(2,2,2-trifluoroacetate)
Title compound was synthesized as per procedure given in step 3 of intermediate 3 by using 6-(((6-(5-trityl-5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)nicotinonitrile to obtained 6-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)- yl)pyridin-2-yl)oxy)methyl)nicotinonitrile bis(2,2,2-trifluoroacetate) Mass m/z 318 [M+H]+
Synthesis of Intermediate 6
5-(2-((5-chloropyridin-2-yl)methoxy)pyrimidin-4-yl)-l,2,3,5-tetrahydropyrrolo[3,4- c]pyrrole bis(2,2,2-trifluoroacetate)
To a solution of 2-trityl- 1,2,3, 5-tetrahydropyrrolo[3,4-c]pyrrole (600 mg, 1.712 mmol), in THF (10 ml), was added potassium tert-butoxide (288 mg, 2.57 mmol) at RT and reaction mixture stirred for 10 min. 2,4-Dichloropyrimidine (383 mg, 2.57 mmol) was then added and reaction mixture stirred at 50°C for 20 hr. After completion of reaction cooled to RT and ice water was added and extracted with ethyl acetate concentrated and purified by column chromatography using 0 to 15% ethyl acetate in hexane to obtained 5- (2-chloropyrimidin-4-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole (160 mg, yield 19%) Mass m/z 463 [M+H]+ Step 2:
Synthesis of 5-(2-((5-chloropyridin-2-yl)methoxy)pyrimidin-4-yl)-2-trityl-l,2,3,5- tetrahydropyrrolo[3,4-c]pyrrole
Title compound was synthesized as per procedure given in step 2 of intermediate 3 by using 5-(2-chloropyrimidin-4-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole and (5- chloropyridin-2-yl)methanol to obtained 5-(2-((5-chloropyridin-2-yl)methoxy)pyrimidin- 4-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole Mass m/z 570.2 [M+H]+ Step 3:
Synthesis of 5-(2-((5-chloropyridin-2-yl)methoxy)pyrimidin-4-yl)-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2-trifluoroacetate)
Title compound was synthesized as per procedure given in step 3 of intermediate 3 by using 5-(2-((5-chloropyridin-2-yl)methoxy)pyrimidin-4-yl)-2-trityl-l,2,3,5- tetrahydropyrrolo[3,4-c]pyrrole to obtained 5-(2-((5-chloropyridin-2- yl)methoxy)pyrimidin-4-yl)-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2- trifluoroacetate) Mass m/z 328 [M+H]
Synthesis of Intermediate 07
5 -(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 1 ,2,3,5 -tetrahydropyrrole [3 ,4- c]pyrrole bis(2,2,2-trifluoroacetate)
Synthesis of 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2-trityl-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole
Title compound was synthesized as per procedure given in step 2 of intermediate 3 by using 5-(2-chloropyrimidin-4-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole and (4- chloro-2-fluorophenyl)methanol to obtained 5-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-2-trityl-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole Mass m/z 587.2 [M+H]+ Step 2:
Synthesis of 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2-trifluoroacetate)
Title compound was synthesized as per procedure given in step 3 of intermediate 3 by using 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2-trityl-l, 2,3,5- tetrahydropyrrolo[3,4-c]pyrrole to obtained 5-(2-((4-chloro-2-fluor obenzyl)oxy)pyrimidin-4-yl)-l,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole bis(2,2,2- trifluoroacetate) Mass m/z 345.0 [M+H]+
Example 14
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol- 2(1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H-benzo[d] imidazole-6-carboxylic acid
Step-1
Synthesis of methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate
To a solution of 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrrol-2(4H)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile bis(2,2,2-trifluoroacetate) (40 mg, 0.071 mmol) in acetonitrile (1 ml) were added potassium carbonate (39.3 mg, 0.284 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (20.96 mg, 0.071 mmol) and reaction mixture was stirred at 60-70 °C for 2 hr. Reaction mixture was cooled to RT charged water and extracted with ethyl acetate. Adsorbed on silica and eluted with 0 to 80 % ethyl acetate in hexane to obtained methyl (S)-2-((5-(6-((4-cyano- 2-fluorobenzyl)oxy)pyridin-2-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (15 mg, yield 36%) Mass m/z 593.3 [M+H]+
Step-2
Synthesis of (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylic acid
To a solution of methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate (15 mg, 0.025 mmol) in acetonitrile (1 ml) was added
aqueous solution of l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (8.81 mg, 0.063 mmol) and reaction mixture was stirred at RT for 20 h. Removed organic solvent and acidify with 10% citric acid sol. To pH 5 to 6. Precipitated solid was filtered and dried. Stirred solid in diethyl ether and filtered to obtained (S)-2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid (8 mg, yield 55%) Mass m/z 579.3 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.34 (s, 1H), 8.01-8.03 (d, J= 8.4Hz, 1H), 7.71-7.77 (m, 3H), 7.57-7.63 (m, 2H), 7.35 (s, 2H), 7.06-7.12 (dd, J= 8.4 Hz & 5.6 Hz, 1H), 6.69- 6.79 (d, J= 8Hz, 1H), 5.58 (s, 2H), 4.65 (bs, 4H), .45-4.48 (m, 4H), 2.76-2.90 (m, 4H), 2.49-2.51 (m, 1H)
Example 15
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1
Synthesis of methyl (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 of Example 17 by using 5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-l,2,3,5-tetrahydropyrrolo[3,4- c]pyrrole bis(2,2,2-trifluoroacetate) (50 mg, 0.087 mmol), K2CO3 (60.3 mg, 0.436 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylate (25.7 mg, 0.087 mmol) to obtained methyl (S)-2-((5-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (40 mg, yield 75 %) Mass m/z 603.1 [M+H]+ Step 2
Synthesis of (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylic acid
This compound was synthesized as per procedure given in step 2 of Example 17 by using methyl (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylate (40 mg, 0.066 mmol) and LiOH (11.12 mg, 0.464 mmol) to obtained (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-2-ylmethyl)- 1 H- benzo[d]imidazole-6-carboxylic acid (12 mg, yield 31 %). Mass m/z = 589.1 [M+H]+
Example 16
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-
Synthesis of methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -((1 -ethyl- 1 H-imidazol-5 -yl)methyl)- 1 H- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 of Example 17 by using 5 -(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)- 1 ,2,3,5 -tetrahydropyrrole [3 ,4- c]pyrrole (15 mg, 0.044 mmol), K2CO3 (30.1 mg, 0.218 mmol) and methyl 2- (chloromethyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6- carboxylate (14.48 mg, 0.044 mmol) to obtained methyl 2-((5-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l- ((1 -ethyl- lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (7 mg, yield 21 %) Mass m/z 641 [M+H]+ Step 2
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo [3 ,4-c]pyrrol-2( 1 H)-yl)methyl)- 1 -((1 -ethyl- 1 H-imidazol-5 -yl)methyl)- 1 H- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 of Example 17 by using methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l -((1 -ethyl- IH-imi dazol-5-yl)methyl)-lH-benzo[d]imi dazole- 6-carboxylate (7 mg, 10.92 pmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (6.08 mg, 0.044 mmol) to obtained 2-((5-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l- ((1 -ethyl- lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid (2.5 mg, yield = 37 %) Mass m/z = 627 [M+H]+
Example 17
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Synthesis of intermediate 8:
Step 1:
Charge 3-fluoro-4-(hydroxymethyl)benzonitrile (1.123 g, 7.43 mmol), 2,6- dichloropyridine (1.0 g, 6.76 mmol) and CESIUM CARBONATE (3.30 g, 10.14 mmol) in ACN (10 ml) at 25°C. Stirred it at 80°C for 16 h. After completion of reaction Filter the solid through Highflow and ml was evaporated under reduced pressure. Crude product was purified by column chromatography using Hexane:EtOAc (950 ml : 50 ml) as a solvent. Wt.= 1 g (Y%=56%)
Synthesis of intermediate 9: tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate Boc
In a 250ml three neck RBF, THF (75ml) was charged and cooled externally with dry ice to -5 to 0°C. Lithium aluminum hydride powder (3.26 g, 86 mmol) was added portion wise, over a period of 15min, while maintaining the internal temperature below 5 °C. Tetrahydrophthalimide (1) (5 g, 33.1 mmol) was added portion wise, over a period of 10
min, maintaining an internal temperature below 5 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was then heated at 66-67 °C for 16 h. The reaction mixture was cooled to room temperature and subsequently up to -10 °C with dry ice. The reaction mixture was quenched with dropwise addition of ice water (75mL), while maintaining an internal temperature below 5 °C. Upon completion of water addition, the reaction mixture turned to a thick slurry. Additional THF (20ml) and solid sodium sulfate were added followed by dropwise addition of KOH solution (15%; 0.58g KOH in 3.8ml water), over a period of 20min, while maintaining an internal temperature below 5 °C. Additional water (10ml) and solid sodium sulfate (2 g) were added, and the reaction mixture was slowly warmed to room temperature. At room temperature it was stirred for another 30 min, and the solid inorganic material was filtered off through a HyFlo SuperCel bed. The inorganic solid impurity was washed twice with THF (2 x 15 ml), and the combined THF layer was dried over sodium sulfate, filtered, and concentrated in vacuo to yield compound 2 2,3,3a,4,7,7a-hexahydro-lH-isoindole as an oil (3.6g) (Y:86%) Mass m/z 124.2 [M+H]+ which was used in the next reaction, without any further purification.
250 ml three neck RBF was charged with compound 2 (3.6 g, 29.2 mmol), dissolved in THF (54ml), and cooled up to 0 to -5 °C. Boc-anhydride (8.48 ml, 36.5 mmol) was added dropwise, while maintaining an internal temperature between 0 and 5 °C, over a period of lOmin. The reaction mixture was warmed to room temperature and stirred at room temperature for 16 h. A solution of glycine (1.755 g, 23.38 mmol) and sodium carbonate (5.27 g, 49.7 mmol) in water (12ml) was added to the reaction mixture at room temperature and stirred for an additional 20 h. The reaction mixture was concentrated under reduced pressure to remove THF and dried under vacuum. The n-Hexane (25 ml) and additional water (8 ml) were added and stirred at room temperature for 15 min. The reaction mixture was filtered through HyFlo SuperCel, and the layers were separated. The aqueous layer was extracted with n-hexane (2 x 20 ml), and the combined organic layer as washed with water (2 x 20 ml) and brine (20 ml). The hexane layer was stirred with
activated charcoal (~500 mg), for 20min at room temperature, and filtered through HyFlo SuperCel. The combined hexane was dried over sodium sulfate, filtered, and concentrated in vacuo to afford compound (3) tert-Butyl 3a,4,7,7a-Tetrahydro-lH-isoindole-2(3H)- carboxylate( (5.4g, 83%) as a brown oil. Mass m/z 124.1 [M+H]+
250ml three neck RBF was charged with a solution of tert-butyl l,3,3a,4,7,7a-hexahydro- 2H-isoindole-2-carboxylate (5.4 g, 24.18 mmol), dissolved in n-pentane (27ml), and cooled externally to 0 °C. A freshly prepared solution of KMnO4 (11.46 g, 72.5 mmol) and TBAB (1.169 g, 3.63 mmol) were dissolved in Water (92 ml) added dropwise while maintaining the inner temperature 0 to -5°C in span of 30 min. The reaction mixture was further stirred at 0-5 °C for 1 h. The reaction mixture was filtered through HyFlo SuperCel, and the residual solid was slurry washed with water (2 x 8 ml). The combined filtrate was washed with ethyl acetate (12ml), and the organic layer was separated. The aqueous layer was acidified with a 1 N HC1 solution (pH ~ 3) and extracted with ethyl acetate (3 x 40 ml). The combined ethyl acetate layer was washed with brine (28 ml), treated with activated charcoal (9g), and filtered through the HyFlo SuperCel. The organic solvent was distilled under vacuum to afford the title compound (7g) as an off- white solid, which was purified by solvent treatment. Ethyl acetate (40ml) was added, and the solid was stirred for 30 min, at room temperature; afterward, n- hexane (8ml) was slowly added, followed by stirring for 90 min. The solid product was fdtered in vacuo and washed with 30% ethyl acetate in n-hexane (1 x 2.5 L). The product was dried for 2 h to yield compound 4 (5.3g, 75%) as a white solid. Mass m/z 286.2 [M-H]+
Step-4: Tert-Butyl (3aR,6aS)-5-Oxohexahydrocyclopenta[c]-pyrrole-2(lH)-carboxylate O=<^£^N- Boc
250 ml three neck RBF was charged with ACETIC ANHYDRIDE (26.1 ml, 277 mmol) followed by slow addition of 2,2'-(l-(tert-butoxycarbonyl)pyrrolidine-3,4-diyl)diacetic acid (5.3 g, 18.45 mmol). The reaction mixture was heated at 135 °C for 45min. Sodium acetate (1.286g, 15.68 mmol) was added to the reaction mixture portion wise, over a
period of 30 min, and additionally, the mixture was stirred at 135 °C for 30 min. The reaction mixture was cooled up to 5-10 °C, and MeOH (10 ml) was added dropwise; while the internal temperature was maintained between 10 and 15 °C, addition of methanol was completed within 2 h, and the reaction mixture was cooled up to -5 °C. The reaction mixture was poured into 10 ml ice water, and slowly solid sodium carbonate (~12 g, pH ~ 10) was added, followed by cyclohexane addition (~50 ml). The reaction mixture was stirred for 15 min and filtered through HyFlo SuperCel to remove solid inorganic waste, and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with cyclohexane (2 x 40 ml). The combined organic solvent was dried over sodium sulfate and concentrated in vacuo.
To afford crude product (~1.44 g). The crude product was purified by reprecipitation from cyclohexane. The crude product was dissolved in cyclohexane (6 ml) at 60 °C. It was allowed to cool gradually to room temperature and then to 5-10 °C in an ice bath, for 1 h. The off white colored solid product was filtered and dried in vacuo to afford pure compound 1 (2.4g, 58%) as a white solid . Mass m/z 226.3 [M+H]+ Step 5:
Preparation of tert-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate
To a solution of tert-butyl 5-oxohexahydrocyclopenta[c]pyrrole-2(lH)-carboxylate (1 g, 4.44 mmol) in THF (20.00 ml). Cool it at 0°C. Charge N- Phenyltrifluoromethanesulfonimide (1.982 g, 5.55 mmol) and LHMDS (7.56 ml, 7.77 mmol) in to it at 0 °C. Stirred it for 1 h at 0 °C. From The reaction mixture was diluted with EtOAc (35 ml) and wash with cold water (15 ml) and brine (15 ml). Organic solvent was concentrated under reduced pressure to afford crude product. Crude product was purified by column chromatography using Hexane:EtOAc (800 ml : 200 ml) as a solvent. Wt.= 1.56 g (Y%=100%) Step 6:
Preparation of tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate Boc
Tert-butyl 5-(((trifhioromethyl)sulfonyl)oxy)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrole- 2(lH)-carboxylate (1.56 g, 4.37 mmol) was dissolve in Dioxane (31.2 ml) charge bis(pinacolato)diboron (1.219 g, 4.80 mmol), potassium acetate (1.285 g, 13.10 mmol) and PdC12(dppf) (0.319 g, 0.437 mmol) in to it under nitrogen at 25 °C.
The reaction mixture was diluted with EtOAC (25 ml) and filter the solid .Organic solvent was concentrated under reduced pressure to afford crude product. Crude product was purified by column chromatography using Hexane: EtOAC (800 ml : 200 ml) as a solvent. Wt.= 1.0 g (%Y=68%)
Coupling:
Step 7:
Preparation of tert-butyl5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate
Dissolve 4-(((6-chloropyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (350 mg, 1.332 mmol) in H2O (0.7 ml) and Dioxane (7.00 ml) at 25°C to give a colourless suspension. Charge tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate (447 mg, 1.332 mmol) in to it at 25 °C.
Charge PdCl2 (dppf) (97 mg, 0.133 mmol) and caesium carbonate (972 mg, 2.98 mmol) in to it at 25 °C and stirred it for 16 h at 90 °C. The reaction mixture was diluted with EtOAc (25 ml) and wash with H2O (15 ml) and brine (15 ml). Organic solvent was concentrated under reduced pressure to afford desired crude product. Crude product was purified by column chromatography using Hexane:EtOAc (900 ml : 100 ml) as a solvent. Wt.= 350 mg (%Y=60%)
Step 8:
Preparation of 3-fluoro-4-(((6-(l,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)pyridin-
To a solution of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrole-2(lH)-carboxylate (350 mg, 0.8 mmol) in EtOAc (7 ml) para toluene sulfonic acid monohydrate (412 mg, 2.17 mmol) was added at 25°C. The reaction mixture was stirred at 60°C for 2 hrs, Filter the solid to obtain 3-fluoro-4-(((6- (l,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)pyridin-2-yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulfonate) (437 mg, 80 % yield).
Step 9:
Methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
3-fluoro-4-(((6-(l,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5-yl)pyridin-2- yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulfonate) (150 mg, 0.17 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (52 mg, 0.17 mmol) was dissolved in Acetonitrile (3 ml) and potassium carbonate (117.3 mg, 0.85 mmol) was added to it and reaction mixture was heated to 60 °C was heated for 2 hr. After completion of reaction, Dilute RM with EtOAc and wash with water and
brine, evaporate the solvent and crude material was purified by combiflash to obtain methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate (120 mg, 92 % yield). Mass [M+H]+ = 594
Step- 10:
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Compound methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrol-5-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate (120 mg, 0.20 mmol) was dissolved in ACN (3.1 ml) Then l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (58.5 mg, 0.42 mmol) in Water (0.5 ml) was added and reaction mixture was stirred at RT for overnight (16 h) After completion of reaction, evaporate the solvent and dilute it with water. Reaction mixture was acidify with 10% citric acid soln. Extract the product with EtOAc (10 ml), wash with H2O (5 ml), brine (5 ml), dried over Na2SO4 and concentrate. Purified the Product through combiflash to obtain 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2- yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid (27 mg, 22.73% yield. Mass [M+H]+ = 580
'H-NMR (400 MHz, DMSO-d6) 5 12.73(bs, 1H), 8.21 (s, 1H), 7.89-7.91 (m, 2H), 7.72- 7.88 (m, 3H), 7.05-7.12(m, 2H), 6.76 (s, 2H), 6.41 (s, 1H), 5.46-5.50 (m, 2H), 4.95 (s, 2H), 4.45 (s, 1H), 4.22-4.24 (m, 2H), 4.04(s, 2H), 3.31-3.43(m, 4H), 2.94(s, 2H), 2.17- 2.19(d, J=6.8Hz, 1H)
Example 18
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1 methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 20 using 3-fluoro-4-(((6-(l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrol-5-yl)pyridin-2-yl)oxy)methyl)benzonitrile bis(4- methylbenzenesulfonate) and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (94 mg, 68.7 % yield).
Step-2:
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Procedure same as written in step 10 in Example 20 using methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2-((5-(6- ((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol- 2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid (15 mg, 16.69 % yield). Mass [M+H]+ = 568.6
'H-NMR (400 MHz, DMSO-d6) 5 8.30 (s, 1H), 7.90-7.93 (m, 2H), 7.74-7.88 (m, 4H), 7.10-7.14(m, 1H), 6.83-6.85 (m, 1H), 6.49 (s, 1H), 5.51 (s, 2H), 4.84 (m, 2H), 4.55 (m, 2H), 3.5-3.9 (m, 9H), 3.24(s, 4H)
Example 19 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- 1 H-benzo [d] imidazole-6-carboxylic acid
Step 1
Methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
Procedure same as written in step 9 in Example 20 using 3-fluoro-4-(((6-(l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrol-5-yl)pyridin-2-yl)oxy)methyl)benzonitrile bis(4- methylbenzenesulfonate) and methyl 2-(chloromethyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (35 mg, 25.1% yield). Mass [M+H]+ = 632.5
Step-2:
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
Procedure same as written in step 10 in Example 20 using methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l -((1 -ethyl-lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-
tetrahydrocyclopenta[c]pyrrol-2( l H)-yl)methyl)-l -(( l -ethyl- l H-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylic acid (15 mg, 43.8% yield). Mass [M+H]+ = 618.5 'H-NMR (400 MHz, DMSO-d6) 5 8.04 (m, 2H), 7.89-7.91 (m, 1H), 7.79 (m, 1H), 7.6- 7.72(m, 3H), 7.50 (m, 1H), 7.01-7.05 (m, 1H), 6.76-6.79 (m, 1H), 6.41 (s, 2H), 5.66 (s, 2H), 5.49 (s, 2H), 3.84(s, 2H), 3.70-3.76(m, 2H), 3.3(m, 4H), 2.9(m, 2H), 1.86-1.89(m,
2H), 0.84-0.91(m, 3H)
Example 20
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1
Preparation of 5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrolebis(4-methylbenzenesulfonate)
Intermediate was synthesized as per procedure given in step 8 Example 1.
Step 2
Methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 20 using 5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,3a,4,6a hexahydrocyclopenta[c]pyrrolebis(4- methylbenzenesulfonate) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (100 mg, 57.1 % yield). Mass [M+H]+ = 603.3
Step-3
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Procedure same as written in step 2 in Example 5 using methyl 2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2- ((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-
tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid ( 85mg, 70.3 % yield. Mass [M+H]+ = 589.
'H-NMR (400 MHz, DMSO-d6) 5 8.23 (s, 1H), 7.5-7.9 (m, 5H), 7.3 (m, 1H), 7.03- 7.10(m, 1H), 6.74 (m, 1H), 6.44-6.49 (m, 1H), 5.4 (s, 2H), 4.98 (m, 1H), 4.67(m, 1H), 4.48(m, 1H), 4.24-4.26(m, 2H), 4.08(m, 1H), 3.48(m, 1H), 2.95-3.04(m, 2H), 2.51- 2.73(m, 5H), 2.33-2.49(m, 3H)
Example 21
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
Step 1
Methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
Procedure same as written in step 9 in Example 20 using 5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-l,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrolebis(4- methylbenzenesulfonate) and methyl 2-(chloromethyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(6-((4-chloro-2-
fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (44 mg, 33.8% yield). Mass [M+H]+ = 641.2
Step-2:
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)-
Procedure same as written in step 2 in Example 5 using methyl 2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l -((1 -ethyl-lH-imidazol-5-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylic acid (25mg, 58.1% yield. Mass [M+H]+ = 627.2 'H-NMR (400 MHz, DMSO-d6) 5 8.06 (s, 1H), 7.82 (d, J=1.6Hz, 1H), 7.67-7.71 (m, 2H), 7.57(m, 2H), 7.45-7.48 (m, 1H), 7.3 (m, 1H), 7.02(m, 1H), 6.74(d, J=8.0Hz, 1H), 6.45(d, J=2.8Hz, 2H), 5.68 (s, 2H), 5.40 (s, 2H), 3.88(m, 2H), 3.77(m, 2H), 3.32-3.39(m, 2H), 2.90(m, 2H), 2.58-2.67(m, 4H), 0.89-0.93(t, J=7.2Hz, 3H)
Example 22
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1
Preparation of 3-fluoro-4-(((2-(l ,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrol-5- yl)pyrimidin-4-yl)oxy)methyl)benzonitrilebis(4-methylbenzenesulfonate)
Intermediate was synthesized as per procedure given in step 8 Example 1.
Step 2
Methyl 2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 20 using 3-fluoro-4-(((2-(l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrol-5-yl)pyrimidin-4-yl)oxy)methyl)benzonitrilebis(4- methylbenzenesulfonate) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(4-((2-fluoro-4- isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)-
yl)methyl)-l -(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (80 mg, 61.1 % yield).
Step-3
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylicacid
Procedure same as writen in step 10 in Example 1 using methyl 2-((5-(4-((2-fluoro-4- isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2- ((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylic acid (20 mg, 25% yield. Mass [M-H] = 579.4 'H-NMR (400 MHz, DMSO-d6) 5 8.53 (m, 1H), 8.16 (m, 1H), 7.91-8.0 (m, 4H), 7.73(m, 2H), 6.76 (m, 1H), 5.53 (s, 2H), 4.94-4.97(m, 1H), 4.58(m, 1H), 4.44(m, 1H), 4.25 (m, 1H), 4.07-4.10 (m, 2H), 3.49(m, 7H), 3.00(m, 2H), 2.33-2.38(m, 2H)
Example 23
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1
Methyl 2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Procedure same as written in step 9 in Example 20 using 3-fluoro-4-(((2-(l,2,3,3a,4,6a- hexahydrocyclopenta[c]pyrrol-5-yl)pyrimidin-4-yl)oxy)methyl)benzonitrilebis(4- methylbenzenesulfonate) and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate to obtain methyl 2-((5-(4-((2-fluoro-4- isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l -(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate(76 mg, 59.2 % yield).
Step-3
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylicacid
Procedure same as written in step 10 in Example 20 using methyl 2-((5-(4-((2-fluoro-4- isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)-
yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate to obtain 2- ((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5-yl)methyl)- lH-benzo[d]imidazole-6-carboxylic acid (20 mg, 27.5 % yield. Mass [M+H]+ = 569 'H-NMR (400 MHz, DMSO-d6) 5 12.73(s, 1H), 8.49 (d, J=5.6Hz,lH), 8.12 (s, 1H), 7.74- 7.79 (m, 3H), 7.62(d, J=8.4Hz, 1H), 6.83 (d, J=5.6Hz, 1H), 6.72 (d, J=2.0Hz, 1H), 5.54(s, 2H), 4.42(m, 2H), 3.92-3.95(m, 1H), 3.81-3.85 (m, 1H), 3.33-3.48 (m, 4H), 2.96-3.00(m, 4H), 2.63-2.68(m, 4H), 1.34(s, 2H)
Example 24
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-
3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-
Title compound was synthesized as per procedure given in step 9 Example 20 by using 2- (6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
4-methylbenzenesulfonate (90 mg, 0.123 mmol), K2CO3 (85 mg, 0.613 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (43.4 mg, 0.147 mmol) to obtained methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5- fluoropyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)- oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (70 mg, yield 66 %) Mass m/z 612.5 [M+H]+ Step 2:
Synthesis of 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 Example 20 by using methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate (70 mg, 0.114 mmol) and l,3,4,6,7,8-hexahydro-2H- pyrimido[l,2-a]pyrimidine (32 mg, 0.227 mmol) to obtained 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a-tetrahydrocyclopenta[c]pyrrol-2(lH)- yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid (20 mg, yield 29 %) Mass m/z 598.4 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 12.5(br s, 1H), 8.2(s,lH),7.93-7.90(d, J=10Hz,lH), 7.80-7.78(d, J=8.4Hz,lH), 7.73-7.62(m, 4H),7.32-7.14(d,J=5.2Hz,lH) 6.39-
6.36(d,J=13.6Hz,lH),5.5(s,2H),4.96-4.44(m, 3H),4.27-4.02(m,2H), 3.45(s,2H), 3.17 - 2.20(m,9H) 1.34(s,lH)
Synthesis of intermediate 10
Cbz
To a cooled solution of sodium hydride (0.287 g, 7.17 mmol) in THF (20 ml), solution of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (1 g, 4.78 mmol) in THF was added lot wise and stir for 5 min. Then benzyl chloroformate (1.501 ml, 5.26 mmol) was added and reaction mixture stirred at room temperature for 1 hrs. Water was added and extracted with ethyl acetate and purified by column with 0 to 20% ethyl acetate in hexane to get 2-benzyl 5-(tert-butyl) pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate (1.2 g, 73.1 % yield). Step 2:
Preparation of benzyl 5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate bis(4- methylbenzenesulfonate)
To a cooled solution of 2-benzyl 5 -(tert-butyl) pyrrolo[3,4-c]pyrazole-2,5(4H,6H)- dicarboxylate (100 mg, 0.291 mmol) in ethyl acetate (2 ml), para-toluenesulfonic acid was added and reaction mixture was stirred at reflux for 3 to 4 hrs. Removed the solvent and oily residue was stirred in diethylether and solution was decanted to obtained benzyl 5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate bis(4-methylbenzenesulfonate) (120 mg, 70.1% yield).
Synthesis of Intermediate 11
4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate)
Step 1
Preparation of tert-butyl 2-(6-chloropyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-
To a solution of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (1.41 g, 6.76 mmol) in DMF (25 ml), 2,6-dichloropyridine (1.0 gm, 6.76 mmol) and CS2CO3 (3.26 g, 16.89 mmol) mmol were added. The reaction mixture was stirred at 85°C for 20 hrs, Reaction mixture was quenched by adding reaction mixture to water. Product was extracted with ethyl acetate. Solvent was dried over sodium sulphate and evaporated. Compound was purified by column chromatography to obtain tert-butyl 2-(6- chloropyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (900 mg, 41.5 % yield). Mass m/z 321.1 [M+H]+
Step 2
Preparation of tert-butyl 2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate
To a clear solution of tert-butyl 2-(6-chloropyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazole-5(4H)-carboxylate (0.1 g, 0.312 mmol) in toluene (1.5 ml) . Degassed it with N2 balloon. 3-fhioro-4-(hydroxymethyl)benzonitrile (49.5 mg, 0.327 mmol), CS2CO3 (259 mg, 0.795 mmole), Johnphos (11 mg, 0.038 mmole) and Pd2(dba)s (17 mg, 0.019 mmol) was added in to it at 25°C. Again degassed it. Reaction mass was stirred at preheated 110-120°C for 16 hrs. Product was diluted with ethyl acetate (15 ml) and filter the solid. Evaporate the solvent under reduced pressure and product was purified by column chromatography to tert-butyl 2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)- 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (80 mg, 59 % yield). Mass m/z 436.1 [M+H]+
Step 3
Preparation of 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile bis(4-methylbenzenesulfonate)
To a tert-butyl 2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazole-5(4H)-carboxylate)(195 mg, 0.448 mmol) in ethyl acetate (3.8 ml) were added 4-methylbenzenesulfonic acid hydrate (230 mg, 1.209 mmol) and reaction mixture was stirred at 60 °C for 2 hrs. After completion of reaction, solvent was removed under
vaccuum to obtain 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile bis(4-methylbenzenesulfonate) (250 mg, 82% yield). Mass m/z 335 [M+H]+
Synthesis of Intermediate 12 2-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole bis(2,2,2-trifluoroacetate)
Step 1
Preparation of tert-butyl 2-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using tert-butyl 2-(6-chloropyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate and (5-chloropyridin-2-yl)methanol to obtained tert-butyl 2-(6-((5- chloropyridin-2-yl)methoxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate Mass m/z 428.2 [M+H]+
Step 2
Preparation of 2-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-2, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazole bis(2,2,2-trifluoroacetate)
To a solution of tert-butyl 2-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (60 mg, 0.140 mmol) in DCM (2.5 ml) was added TFA (0.108 ml, 1.402 mmol) and reaction mixture was stirred at RT for 6 hr. After completion of reaction, solvent was removed and stirred solid in diethyl ether and filtered and dried to obtained 2-(6-((5-chloropyridin-2-yl)methoxy)pyridin-2-yl)-2, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazole bis(2,2,2-trifluoroacetate) (75 g, yield = 96%) Mass m/z 328.2 [M+H]+
Synthesis of Intermediate 13 6-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2- yl)oxy)methyl)nicotinonitrile bis(2,2,2-trifluoroacetate)
Step 1
Preparation of tert-butyl 2-(6-((5-cyanopyridin-2-yl)methoxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using tert-butyl 2-(6-chloropyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate and 6-(hydroxymethyl)nicotinonitrile to obtained tert-butyl 2-(6-((5-
cyanopyridin-2-yl)methoxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate Mass m/z 419.3 [M+H]+
Step 2
Preparation of 6-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2- yl)oxy)methyl)nicotinonitrile bis(2,2,2-trifluoroacetate)
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using tert-butyl 2-(6-((5-cyanopyridin-2-yl)methoxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate to obtained 6-(((6-(5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)nicotinonitrile bis(2,2,2- trifluoroacetate) Mass m/z 319.2 [M+H]+
Synthesis of Intermediate 14
2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole bis(4-methylbenzenesulfonate
Step 1
Preparation of tert-butyl 2-(2-chloropyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole- 5(4H)-carboxylate
Boc
Title compound was synthesized as per procedure given in step 1 of intermediate 11 by using tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate and 2,4- dichloropyrimidine to obtained tert-butyl 2-(2-chloropyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate Mass m/z 322.2 [M+H]+ Step 2
Preparation of tert-butyl 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using tert-butyl 2-(2-chloropyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate and (4-chloro-2-fluorophenyl)methanol to obtained tert-butyl 2-(2-((4- chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate Mass m/z 446.2 [M+H]+
Step 3
Preparation of 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazole bis(4-methylbenzenesulfonate)
Title compound was synthesized as per procedure given in step 3 of intermediate 11 by using tert-butyl 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-
dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate to obtained 2-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bis(4- methylbenzenesulfonate) Mass m/z 346.1 [M+H]+
Synthesis of Intermediate 15
4-(((4-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate)
Step 1
Preparation of tert-butyl 2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using tert-butyl 2-(2-chloropyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate and 3-fluoro-4-(hydroxymethyl)benzonitrile to obtained tert-butyl 2-(2-((4- cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)- carboxylate Mass m/z 437.2 [M+H]+
Step 2
Preparation of 4-(((4-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-2- yl)oxy)methyl)-3-fluorobenzonitrile bis(4-methylbenzenesulfonate)
Title compound was synthesized as per procedure given in step 3 of intermediate 11 by using tert-butyl 2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate to obtained 4-(((4-(5,6- dihydropyrrolo [3, 4-c]pyrazol-2(4H)-yl)pyrimidin-2-yl)oxy)methyl)-3 -fluorobenzonitrile bis(4-methylbenzenesulfonate) Mass m/z 337.1 [M+H]+
Synthesis of Intermediate 16
5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole trihydrobromide
Title compound was synthesized as per procedure given in step 1 of intermediate 11 by using benzyl 5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate and 2,6- dichloropyridine to obtained benzyl 5-(6-chloropyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate Mass m/z 355.2 [M+H]+
Step 2
Preparation of benzyl 5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 12 by using benzyl 5-(6-chloropyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate and (4-chloro-2-fluorophenyl)methanol to obtained benzyl 5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate Mass m/z 479 [M+H]+
Step 3
Preparation of 5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6- tetrahydropyrrolo[3,4-c]pyrazole trihydrobromide
To a cooled solution of benzyl 5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate (350 mg, 0.731 mmol) in AcOH (4 ml) was added 33% hydrobromic acid in acetic acid (0.962 ml, 5.85 mmol) and reaction mixture stirred at RT for 18 hr. After completion of reaction, acetic acid was removed solvent and solid stirred in diethyl ether filtered and dried to obtained (Yield: 300 mg, 70%). Mass m/z 345 [M+H]+
Synthesis of Intermediate 17
4-(((6-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile trihydrobromide
Step 1
Preparation of benzyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using benzyl 5-(6-chloropyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate and 3-fluoro-4-(hydroxymethyl)benzonitrile to obtained benzyl 5-(6-((4- cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate Mass m/z 470.2 [M+H]+
Step 2
Preparation of 4-(((6-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile trihydrobromide
Title compound was synthesized as per procedure given in step 3 of intermediate 11 by using benzyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate to obtained 4-(((6-(2,6-dihydropyrrolo[3,4-c]pyrazol-
5(4H)-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile trihydrobromide Mass m/z 336.1 [M+H]+
Synthesis of Intermediate 18
4-(((6-(4,6-dihydropyrrolo[3 ,4-c] pyrazol-5 ( 1 H)-yl)pyridin-2-yl)oxy)methyl)-3 - fluorobenzonitrile trihydrobromide
Step 1
Preparation of benzyl 5-(6-chloropyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-l (decarboxylate
Cbz
Title compound was synthesized as per procedure given in step 1 of intermediate 11 by using benzyl 5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate bis(2,2,2- trifluoroacetate) and 2,6-dichloropyridine to obtained benzyl 5-(6-chloropyridin-2-yl)- 5,6-dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate. Mass m/z 355.2 [M+H]+ Step 2
Preparation of benzyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate
Title compound was synthesized as per procedure given in step 2 of intermediate 11 by using benzyl 5-(6-chloropyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole- l (4H)- carboxylate
3-fluoro-4-(hydroxymethyl)benzonitrile to obtained benzyl 5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate
Mass m/z 470.2 [M+H]+
Step 3
Preparation of 4-(((6-(4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile trihydrobromide
Title compound was synthesized as per procedure given in step 3 of intermediate 11 by using benzyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate to obtained 4-(((6-(4,6-dihydropyrrolo[3,4-c]pyrazol- 5(lH)-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile trihydrobromide Mass m/z 336.1 [M+H]+
Example 25
(S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Preparation of methyl (S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methyl benzenesulfonate) (52 mg, 0.077 mmol) and methyl (S)-2- (chloromethyl)-l -(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, 0.085 mmol) was dissolved in acetonitrile (2 ml) and potassium carbonate (46.9 mg, 0.339 mmol) was added to it and reaction mixture was heated to 60 °C was heated overnight. After completion of reaction, solvent was evaporated and crude material was purified by combi flash to obtain methyl (S)-2-((2-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (45 mg, 0.076 mmol, 98 % yield). Mass 594 [M+H]+ Step 2:
Synthesis of (S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
To a solution of methyl (S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (45 mg, 0.076 mmol) in ACN (1 ml) aqueous solution of l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (0.152 mmol) was added, at RT and stirred for 20 hrs. After completion of reaction, solvent was evaporated and charged 10% citric acid solution till pH 6 to 6.5 and solid was filtered and wash with water and dry to obtain (S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid (5 mg, 12% yield). Mass 579 [M+H]+
'H-NMR (400 MHz, DMSO-d6) 5 12.76.00 (s, 1H), 8.17 (s,lH), 8.37 (s, 1H), 7.89-7.92 (m,3H), 7.47-7.51 (m, 4H), 6.81-6.83 (d, 1H), 5.37 (s, 2H), 5.06-5.07 (d, 1H), 4.62-4.64 (m, 2H), 4.68-4.70 (m, 4H), 3.83-3.85 (m, 4H), 2.54-2.72 (m, 2H)
Example 26
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol- 5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo-imidazole-6-carboxylic acid
Preparation of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo- imidazole-6-carboxylate
4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (90 mg, 0.132 mmol) and methyl 2- (chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (37.4 mg, 0.132 mmol) was dissolved in Acetonitrile (2 ml) and potassium carbonate (73.2 mg, 0.530 mmol) was added to it and reaction mixture was heated to 60 °C for overnight. After completion of reaction, solvent was evaporated and crude material was purified by combi flash to methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo- imidazole-6-carboxylate (68 mg, 0.117 mmol, 88 % yield). Mass 582 [M+H]+ Step 2:
Synthesis of 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo- imidazole-6-carboxylic acid
To a solution of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate (43 mg, 0.074 mmol) acetonitrile (1 ml) was added in aq solution of l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (0.0205 g, 0.147 mmol) at room temperature and stirred for 20 hrs. After completion of reaction, solvent
was evaporated and charged 10% citric acid solution till pH 6 to 6.5 and solid was filtered and wash with water and dry to obtain 2-((2-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2- methoxyethyl)-lH-benzo-imidazole-6-carboxylic acid (6 mg, 10.57 mmol, 14% yield). Mass 568 [M+H]+
'H-NMR (400 MHz, DMSO-d6) 5 12.76.00 (s, 1H), 8.17 (s,lH), 8.37 (s, 1H), 7.89-7.91 (m,3H), 7.66-7.70 (m,3H) 7.47-7.51 (m,4H), 6.81-6.83 (d, 1H), 5.37 (s, 2H), 5.06-5.07 (d, 1H), 4.62-4.64 (m, 2H), 4.29-4.31 (m, 4H),3.33 (s, 3H)
Example 27
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-
Step 1:
Synthesis methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 4- (((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (90 mg, 0.132 mmol), K2CO3 (73.2 mg, 0.530 mmol) and methyl 2-(chloromethyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylate (41.3 mg, 0.146 mmol) to obtained methyl 2-((2-(6-((4-cyano-
2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-3- (2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (25 mg, yield 32 %) Mass m/z 583.4 [M+H]+
Step 2:
Synthesis of 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5- b]pyridine-5-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 29 by using methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5- carboxylate (20 mg, 0.034 mmol) and 1 l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (16.73 mg, 0.120 mmol) to obtained 2-((2-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-3-(2- methoxyethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (12 mg, yield = 62 %) Mass m/z = 569.4 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 13.00 (bs, 1H), 8.32 (s, 1H), 8.14-8.16 (d, J= 8.4 Hz, 1H), 7.99-8.01 (d, J= 8.4 Hz, 1H), 7.85-7.94 (m, 2H), 7.72-7.80 (m, 2H), 7.39-7.41 (d, J= 8.0 Hz, 1H), 6.78-6.80 (d, J= 8 Hz, 1H), 5.57 (s, 2H), 4.62-4.65 (t, 2H), 4.39 (s, 2H), 3.91-3.94 (m, 4H), 3.76-3.78 (t, 2H), 3.24 (s, 3H)
Example 28
(2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1: Synthesis of methyl 2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole bis(4-methylbenzenesulfonate) (100 mg, 0.145 mmol), K2CO3 (100 mg, 0.724 mmol) and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylate (41.0 mg, 0.145 mmol) to obtained methyl 2-((2-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, yield 29 %) Mass m/z 592.3 [M+H]+ Step 2:
Synthesis of (2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
This compound was synthesized as per procedure given in step 2 Example 29 by using methyl 2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, 0.042 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (11.75 mg, 0.084 mmol) to obtained 8 mg (yield = 33 %) Mass m/z = 578.3 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.61-8.62 (d, J= 5.6 Hz, 1H), 8.38 (s, 1H), 8.19 (s, 1H), 7.80-7.82 (d, J= 7.6 Hz, 1H), 7.61-7.66 (m, 2H), 7.46-7.53 (m, 2H), 7.33-7.35 (d, J= 8 Hz, 1H), 5.48 (s, 2H), 4.59-4.61 (t, 2H), 4.33 (s, 2H), 3.93 (s, 2H), 3.86 (s, 2H), 3.68- 3.70 (t, 2H), 3.19 (s, 3H)
Example 29
(S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Synthesis of (methyl (S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 4-(((4-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (100 mg, 0.147 mmol), K2CO3 (102 mg, 0.735 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (43.3 mg, 0.147 mmol) to obtained methyl (S)-2-((2-(2- ((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, yield 29 %) Mass m/z 595.4 [M+H]+ Step 2:
Synthesis of (S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 29 by using methyl (S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (25 mg, 0.042 mmol) and l,3,4,6,7,8-hexahydro-2H- pyrimido[l,2-a]pyrimidine (17.56 mg, 0.126 mmol) to obtained (S)-2-((2-(2-((4-cyano-2- fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid (8 mg, yield 33 %) Mass m/z 581.4 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.62-8.63 (d, J= 5.6 Hz, 1H), 8.37 (s, 1H), 8.25 (s, 1H), 7.93-7.95 (d, J= 9.6 Hz, 1H), 7.74-7.82 (m, 3H), 7.64-7.66 (d, J= 8.4 Hz, 1H), 7.47- 7.49 (d, J= 5.2 Hz, 1H), 5.58 (s, 2H), 5.06-5.07 (d, J= 4.8Hz, 1H), 4.62-4.82 (m, 2H), 4.29-4.50 (m, 4H), 3.83-3.98 (m, 4H), 2.50-2.72 (m, 2H)
Example 30
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol- 5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (90 mg, 0.132 mmol), K2CO3 (91 mg, 0.662 mmol) and methyl 2-(chloromethyl)-l -((3 -methoxy oxetan-3 -yl)methyl)-lH- benzo[d]imidazole-6-carboxylate (43.0 mg, 0.132 mmol) to obtained methyl 2-((2-(6-((4- cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (55 mg, yield 66 %) Mass m/z 624.1 [M+H]+
Step 2:
Synthesis of 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
This compound was synthesized as per procedure given in step 2 Example 29 by using methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6- carboxylate (50 mg, 0.080 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (33.5 mg, 0.241 mmol) to obtained 2-((2-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- ((3 -methoxy oxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid (18 mg, yield = 37 %) Mass m/z = 610.1 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 12.80 (bs, 1H), 8.29 (s, 1H), 8.34 (s, 1H), 7.72-7.93 (m, 4H), 7.72-7.74 (d, J= 8.0 Hz, 1H), 7.66-7.68 (d, J= 8.4 Hz 1H), 7.39-7.41 (d, J= 8.0 Hz, 1H), 6.78-6.80 (d, J= 8.0 Hz, 1H), 5.56 (s, 2H), 4.95 (s, 2H), 4.69-4.71 (d, J= 7.6 Hz, 2H), 4.50-4.52 (d, J= 7.6 Hz, 2H), 4.36 (s, 2H), 3.87-3.91 (s, 4H), 3.43 (s, 3H)
Example 31
(S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl (S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 2- (6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-methylbenzenesulfonate (150 mg, 0.290 mmol), K2CO3 (201 mg, 1.451 mmol) and methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (86 mg, 0.290 mmol) to obtained methyl (S)-2-((2-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (84 mg, yield 48 %) Mass m/z 603.1 [M+H]+ Step 2:
Synthesis of (S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 29 by using methyl (S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (84 mg, 0.139 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (40.3 mg, 0.290 mmol) to obtained (S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-
dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic (35 mg, yield 42 %) Mass m/z 589 [M+H]+
'H-NMR (400 MHz, DMSO-d6) 5 12.83(bs, 1H), 8.35 (s, 1H), 8.27 (s, 1H), 7.85-7.87 (m, 2H), 7.51-7.59(m, 2H), 7.4-7.48 (m, 1H), 7.34-7.38 (m, 1H), 7.32(m, 2H), 6.74(s, 1H), 5.47-5.76(m, 3H), 4.04(m, 1H), 3.87-3.85 (m, 4H)
Example 32
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol- 5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 2- (6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-methylbenzenesulfonate (150 mg, 0.290 mmol), K2CO3 (201 mg, 1.451 mmol) and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (82 mg, 0.290 mmol) to obtained methyl 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2- yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l -(2-methoxy ethyl)- 1H- benzo[d]imidazole-6-carboxylate (113 mg, yield 66 %) Mass m/z 591.1 [M+H]+
Step 2:
Synthesis of 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 29 by using methyl 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (113 mg, 0.191 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (55.4 mg, 0.398 mmol) to obtained 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid (50 mg, yield 45 %) Mass m/z 577.1 [M+H]+ 'H-NMR (400 MHz, DMSO-d6) 5 12.64(bs, 1H), 8.35 (s, 1H), 8.20-8.23 (m, 2H), 7.83- 7.86(m, 2H), 7.60-7.71 (m, 4H), 6.74(d, J=8.0Hz, 1H), 5.47 (s, 2H), 4.61 (s, 2H), 4.34(s, 2H), 3.88-3.92(s, 4H), 3.69-3.71(m, 1H), 3.14-3.26(s, 3H)
Example 33
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol- 5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 29 by using 2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole 4-methylbenzenesulfonate (150 mg, 0.290 mmol), K2CO3 (201 mg, 1.451 mmol) and methyl 2-(chloromethyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate (94 mg, 0.290 mmol) to obtained methyl 2-((2-(6-((4- chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (105 mg, yield 57 %) Mass m/z 633.1 [M+H]+ Step 2:
Synthesis of 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 29 by using methyl 2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6- carboxylate (105 mg, 0.166 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (48 mg, 0.345 mmol) to obtained 2-((2-(6-((4-chloro-2-
fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-
((3 -methoxy oxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid
(30 mg, yield 29 %) Mass m/z 619 [M+H]+
'H-NMR (400 MHz, DMSO-d6) 5 12.83(bs, 1H), 8.34 (s, 2H), 7.84-7.86 (m, 2H), 7.48- 7.51(m, 2H), 7.38-7.40 (m, 2H), 7.31-7.34(m, 2H), 6.73-6.75(m, 1H), 5.46 (s, 2H), 4.96 (s, 1H), 4.69-4.71(m, 2H), 4.50(d, J=7.6Hz, 2H), 4.37(s, 2H), 3.88-3.92(m, 4H), 3.26- 3.43(m, 3H)
Example 34
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Preparation of methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate.
To a solution of 4-(((6-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)pyridin-2- yl)oxy)methyl)-3-fluorobenzonitrile trihydrobromide (30 mg, 0.052 mmol) in acetonitrile (2 ml) were added methyl (S)-2-(chloromethyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (15.30 mg, 0.052 mmol) and potassium carbonate (43.0
mg, 0.311 mmol) and reaction mixture was stirred at 60 ° for 3 hrs. After completion of reaction, diluted with water and extracted with ethyl acetate and purified by column with 0 to 90 % ethyl acetate in hexane to obtain methyl (S)-2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate ( 10 mg, 33% yield). Mass 594 [M+H]+
Step 2:
Preparation of (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
To a solution of methyl (S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (10 mg, 0.017 mmol) in acetonitrile (2 ml) was added aqueous solution of l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (4.69 mg, 0.034 mmol) at room temperature and stirred for 20 hrs. After completion of reaction, solvent was removed and charged 10 % citric acid solution till pH 6 to 6.5 and solid was filtered and wash with water and dry to obtain (S)-2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid (4 mg, 41% yield). Mass 580 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.33 (s, 1H), 8.24 (s, 1H), 7.72-7.93 (m, 5H), 7.66 (s, 1H), 7.39-7.41 (d, J= 8.0 Hz 1H), 6.78-6.80 (d, J= 8.0 Hz, 1H), 5.57 (s, 2H), 5.01 (s, 2H), 4.79 (s, 2H), 4.29-4.66 (m, 3H), 3.65-3.90 (m, 4H), 2.50-5.72 (m, 2H)
Example 35
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid compound with 2,2,2-trifluoroacetic acid
Step 1:
Synthesis of methyl (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 38 by using 5- (6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole trihydrobromide (100 mg, 0.170 mmol), K2CO3 (118 mg, 0.851 mmol) and methyl (S)-2- (chloromethyl)-l -(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (50.2 mg, 0.170 mmol) and to obtained methyl (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin- 2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (25 mg, yield 24 %) Mass m/z 603 [M+H]+ Step 2:
Synthesis of (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid compound with 2,2,2-trifluoroacetic acid
Title compound was synthesized as per procedure given in step 2 Example 38 by using methyl (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (20 mg, 0.033 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (13.85 mg, 0.099 mmol) to obtained (S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)- 5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid compound with 2,2,2-trifluoroacetic acid (1.8 mg, yield 8 %) Mass m/z 589 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 13.00 (bs, 1H), 8.47 (s, 1H), 8.33-8.35 (d, J= 8.0 Hz, 1H), 7.89-7.91 (d, J= 7.6 Hz 1H), 7.87 (s, 1H), 7.75-7.77 (d, J= 8.0 Hz 1H), 7.63-7.65 (d, J= 8.4 Hz, 1H), 7.50-7.52 (d, J= 8.0 Hz, 1H), 7.42-7.44 (d, J= 8.0 Hz, 1H), 7.33-7.35 (d, J= 7.6 Hz, 1H), 6.80-6.82 (d, J= 7.6 Hz, 1H), 5.48 (s, 2H), 5.06-5.07 (d, J = 5.2Hz, 1H), 4.88-4.92 (m, 2H), 4.77-4.82 (m, 2H), 4.29-4.67 (m, 6H), 2.67-2.75 (m, 1H), 2.30-2.45 (m, 1H)
Example 36
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol- 2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 38 by using 5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4- c]pyrazole trihydrobromide (100 mg, 0.170 mmol), K2CO3 (118 mg, 0.851 mmol) and methyl 2-(chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (57.7 mg, 0.204 mmol) to obtained methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2- yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l -(2-methoxy ethyl)- 1H- benzo[d]imidazole-6-carboxylate (25 mg, yield 25 %) Mass m/z 591 [M+H]+ Step 2:
Synthesis of 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 38 by using methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (20 mg, 0.034 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (14.13 mg, 0.102 mmol) to obtained 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid (4 mg, yield = 17 %) Mass m/z = 577 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) 5 13.03 (bs, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 7.90-8.05 (m, 2H), 7.7534-7.77 (m, 5H), 6.83 (s, 1H), 5.48 (s, 2H), 4.91 (s, 2H), 4.06-4.61 (m, 6H), 3.81 (s, 3H), 3.22 (s, 2H)
Ill
Example 37
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-
Step 1:
Synthesis of methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 38 by using 5- (6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole trihydrobromide (40 mg, 0.068 mmol), K2CO3 (37.59 mg, 0.272 mmol) and methyl 2- (chloromethyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (22 mg, 0.068 mmol) to obtained methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin- 2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3- yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (20 mg, yield 46 %) Mass m/z 633 [M+H]+ Step 2:
Synthesis of 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 38 by using methyl 2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)- 1 -((3 -methoxy oxetan-3 -yl)m ethyl)- 1 H-benzo [d] imidazole-6- carboxylate (20 mg, 0.032 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (13.19 mg, 0.095 mmol) to obtained 2-((5-(6-((4-chloro-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l- ((3 -methoxyoxetan-3-yl)methyl)-l H-benzo [d]imidazole-6-carboxylic acid (3.5 mg, yield = 15 %) Mass m/z = 619 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 12.92 (s, 1H), 8.61 (s, 1H), 8.58 (s, 1H), 7.90 (s, 1H), 7.86-7.88 (d, J= 8.8 Hz 1H), 7.32-7.79 (m, 5H), 6.81-6.83 (d, J= 8.8 Hz, 1H), 5.48 (s, 2H), 4.95 (s, 2H), 4.61-4.74 (m, 4H), 4.51-4.53 (d, J= 7.6 Hz, 2H), 4.15-4.29 (m, 4H), 3.45 (s, 3H)
Example 38
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-
Step 1:
Synthesis of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 Example 38 by using 4-(((6-(2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile trihydrobromide (80 mg, 0.138 mmol, K2CO3 (77 mg, 0.554 mmol) and methyl 2-(chloromethyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH-benzo[d]imidazole- 6-carboxylate (49.4 mg, 0.152 mmol) to obtained methyl 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l- ((3 -methoxy oxetan-3-yl)methyl)-lH-benzo[d]imidazole-6-carboxylate (50 mg, yield 58 %) Mass m/z 624.1 [M+H]+ Step 2:
Synthesis of 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6- dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 Example 38 by using methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)- 1 -((3 -methoxy oxetan-3 -yl)m ethyl)- 1 H-benzo [d] imidazole-6- carboxylate (50 mg, 0.080 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2- a]pyrimidine (22.32 mg, 0.160 mmol) to obtained 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-l- ((3 -methoxyoxetan-3-yl)methyl)-l H-benzo [d]imidazole-6-carboxylic acid (12 mg, yield = 25%) Mass m/z = 610.1 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 5 8.33 (s, 1H), 8.29 (s, 1H), 7.72-7.88 (m, 5H), 7.63- 7.66 (d, J= 8.8Hz, 1H), 7.39-7.41 (d, J= 7.6Hz, 1H), 6.78-6.80 (d, J= 7.6 Hz, 1H), 5.56 (s, 2H), 4.94 (s, 2H), 4.69-4.70 (d, J= 7.2 Hz, 2H), 4.63-4.65 (d, J= 6.4 Hz, 2H), 4.36 (s, 2H), 3.80-3.96 (m, 4H), 3.43 (s, 3H)
Example 39
(S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1
Synthesis of methyl (S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 of example 38 using 4- (((2-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-4-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (90 mg, 0.132 mmol), methyl (S)-2- (chloromethyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (42.9 mg, 0.145 mmol) with K2CO3 (91 mg, 0.661 mmol) to methyl (S)-2-((2-(4-((4-cyano-2-
fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (26 mg, 31% yield) mass m/z [M+H]+ = 595
Step- 2
Synthesis of (S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 of example 38 methyl (S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (20 mg, 0.034mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine
(9.36 mg, 0.067 mmol) to obtain (S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin- 2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid. (18 mg, 86% yield) mass m/z [M+H]+ = 581
1H-NMR (400 MHz, DMSO-d6) 5 8.55 (s, 1H), 8.55-8.54 (d, J= 5.6 Hz, 1H), 8.27 (s, 1H), 7.93-7.95 (d, J= 9.6 Hz, 1H), 7.89-7.81 (m, 3H), 7.77-7.75 (d, J= 8 Hz, 1H), 7.68- 7.66 (d, J= 8 Hz, 1H), 5.64 (s, 2H), 5.08-5.07 (d, J= 4 Hz, 1H), 4.67-4.84 (m, 2H), 4.33- 4.50 (m, 4H), 3.97-3.94 (m, 4H), 2.50-2.72 (m, 2H)
Example 40
2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step 1
Synthesis of methyl 2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 1 of example 38 using 4- (((2-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-4-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (90 mg, 0.132 mmol), methyl 2- (chloromethyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (41.1 mg, 0.145 mmol) with K2CO3 (91 mg, 0.661 mmol) to obtain methyl 2-((2-(4-((4-cyano-2- fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l- (2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (50 mg, 64.9 % yield) mass m/z [M+H]+ = 583 Step- 2
Synthesis of 2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 2 of example 38 using methyl 2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (50 mg, 0.086 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (23. 89 mg, 0.172 mmol) to obtain 2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid (15 mg, 29.5 % yield) mass m/z [M+H]+ = 569 1H-NMR (400 MHz, DMSO-d6) 5 8.55 (s, 1H), 8.37-8.33 (d,J=16 ,1H), 8.18 (s, 1H), 7.95-7.93 (d, J= 8 Hz, 1H), 7.89-7.85 (m, 2H), 7.82-7.80 (m, 2H), 7.77-7.75 (d, J= 8 Hz, 1H), 5.64 (s, 2H), 4.61(s, 2H), 4.33 (s, 2H), 3.91 (s, 2H), 3.86 (d, 2H), 3.71-69 (d, 2H), 329 (d, 3H)
Intermediate 19 :
Methyl 2-(chloromethyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate -nitro-3-((oxetan-3-ylmethyl)amino)benzoate
Oxetan-3-ylmethanamine (175 mg, 2.009 mmol) was dissolved in THF (20 ml) was followed by addition of methyl 3-fluoro-4-nitrobenzoate (400 mg, 2.009 mmol). To the reaction mixture TEA (1.6 ml, 11.48 mmol) was added. The reaction mixture was kept to completion at 60-70 °C for 1.5 to 2 hours. TLC was checked for completion of reaction. During work-up water was added into it and extract it with EA. After evaporation this crude was purify by combiflash. 450 mg, yield 90%)
Step-2
To a solution of methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate (450 mg, 1.690 mmol) in THF (1.5 ml) was added Pd-C (90 mg, 0.085 mmol) and RM stirred under H2 balloon pressure till disappearance of yellow color to became colorless RM, about 1 hrs. TLC-complies. Filtered through celite and concentrated under below 40 °C bath temp. To get light brown oily compound. (380 mg, yield 86%) Mass m/z 237 [M+H]+
Step-3
To a solution of methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate (380 mg, 1.608 mmol) in ACN (3.5 ml) were added pTsOH (30.6 mg, 0.161 mmol) and 2-chl oro-1, 1,1- trimethoxy ethane (373 mg, 2.412 mmol) at RT and heated to 60 °C for 5 hrs. TLC- complies. Directly adsorbed on silica and eluted with 0 to 60 % EA in hexane (253 mg, yield 52%) Mass m/z 295.1 [M+H]+
Example 41
2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid
Step-1
Synthesis of methyl 2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 example- 1 by using 4- (((4-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyrimidin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) and methyl 2-(chloromethyl)-l-(2- methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate to obtained methyl 2-((2-(2-((4- cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, yield 48 %) Mass m/z 583.4 [M+H]+ Step-2
Synthesis of 2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 example- 1 by using methyl 2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylate to obtained 2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6-carboxylic acid (12 mg, yield 45.6%) Mass m/z 569.5 [M+H]+
1H-NMR (400 MHz, DMSO-d6) 8.5 (d, J=5.6Hz,lH), 8.21 (s, 2H), 8.07 (d, J=8.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.72 (t, J = 7.4 Hz, 1H), 7.54-7.28 (m, 3H), 5.6(s, 2H), 4.64 (t, J = 5.2 Hz, 2H), 4.28 (s, 2H), 3.98 (s, 2H), 3.93 (s, 2H), 3.76 (t, J = 5.2 Hz, 2H), 3.33 (s, 3H).
Example 42
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-3 -ylmethyl)- 1 H-benzo [d] imidazole-6-carboxylic acid
Synthesis of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 Example 1 by using 3- fluoro-4-(((6-(3 ,4, 5,6-tetrahydropyrrolo [3 ,4-c] pyrrol-2( 1 H)-yl)pyridin-2- yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulfonate) (63 mg, 0.093 mmol), potassium carbonate (63.9 mg, 0.463 mmol) and methyl 2-(chloromethyl)-l-(oxetan-3- ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (24.55 mg, 0.083 mmol), to obtained methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (24 mg, yield 44 %) Mass m/z 595.4 [M+H]+ Step 2: 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-3 -ylmethyl)- 1 H-benzo [d] imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 Example 1 by using methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (24 mg, 0.040 mmol) and l,3,4,6,7,8-hexahydro-2H- pyrimido[l,2-a]pyrimidine (11.69 mg, 0.084 mmol) to obtained 2-((5-(6-((4-cyano-2- fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)- l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylic acid (5 mg, yield 18%) Mass m/z 581.4 [M+H]+
'H-NMR (400 MHz, DMSO-d6) 5 8.36 (s, 1H), 7.86-7.89 (m, 4H), 7.68-7.75(m, 3H), 7.49 (s, 1H), 6.11(d, J=8.0Hz, 2H),5.45 (s, 2H), 4.71-4.73 (m, 2H), 4.59-4.63(m, 2H), 4 45-448(m, 4H), 4.15(m, 8H)
Example 43
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyrazin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid
Step 1:
Synthesis of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 Example 1 by using 3 4-(((6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-2-yl)oxy)methyl)-3- fluorobenzonitrile bis(4-methylbenzenesulfonate) (100 mg, 0.147 mmol), K2CO3 (102 mg, 0.736 mmol) and methyl 2-(chloromethyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (43.4 mg, 0.147 mmol) to obtained methyl 2-((2-(6-((4- cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)- yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (25 mg, yield 29 %) Mass m/z 594.4 [M+H]+
Step 2:
Synthesis of 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 Example 1 by using methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (20 mg, 0.034 mmol) and l,3,4,6,7,8-hexahydro-2H-pyrimido[l,2-a]pyrimidine (9.38 mg, 0.067 mmol)to obtained 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid (8 mg, yield 41%) Mass m/z 580.4 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) 5 12.90 (s, 1H), 8.31 (s, 1H), 8.27 (s, 1H), 7.67-7.93 (m, 5H), 7.67-7.69 (d, J= 7.6Hz, 1H), 7.39-7.41 (d, J= 7.6 Hz, 1H), 6.78-6.80 (d, J= 7.6Hz, 1H), 5.57 (s, 2H), 4.75-4.77 (d, J=7.6Hz, 2H), 4.48-4.59 (m, 4H), 4.33 (s, 2H), 3.87-3.91 (m, 4H), 3.57-3.63 (m, 1H)
Example 44
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2( 1 H)-yl)methyl)- 1 -(oxetan-3 -ylmethyl)- 1 H-benzo [d] imidazole-6-carboxylic acid
Step-1
Synthesis of methyl (S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate
Title compound was synthesized as per procedure given in step 9 Example 1 by using 3- fluoro-4-(((4-(3 ,4, 5,6-tetrahydropyrrolo [3 ,4-c] pyrrol-2( 1 H)-yl)pyrimidin-2- yl)oxy)methyl)benzonitrile bis(4-methylbenzenesulf onate) (100 mg, 0.147 mmol), K2CO3 (101 mg, 0.733 mmol) and methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)- 3H-imidazo[4,5-b]pyridine-5-carboxylate (44mg, 0.147 mmol) to obtained methyl 2-((5- (2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol- 2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6-carboxylate (50 mg, yield 57%) Mass m/z 596.5 [M+H]+
Step-2
Synthesis of 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid
Title compound was synthesized as per procedure given in step 10 Example 1 by using methyl 2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylate (0.05 g, 0.083 mmol) and 1,3, 4,6,7, 8-hexahydro-2H-
pyrimido[l,2-a]pyrimidine (24 mg, 0.172 mmol) to obtained 2-((5-(2-((4-chloro-2- fluorobenzyl)oxy)pyrimidin-4-yl)-3 ,4, 5 ,6-tetrahydropyrrolo [3 ,4-c]pyrrol-2( 1 H)- yl)methyl)- 1 -(oxetan-3 -ylmethyl)- 1 H-benzo [d] imidazole-6-carboxylic acid (5 mg, yield 7 %) Mass m/z 591.4 [M+H]
1H-NMR (400 MHz, DMSO-d6) 5 12.9O(1H, s), 8.3O(1H, s), 8.1O(1H, dd, J=12.3Hz& J=4.3Hz), 8.02(lH, dd, J=11.2&J=5.6Hz), 7.87(1H, d, J=7.2Hz), 7.81(1H, s), 7.3O(1H, d, 9Hz), 7.25(1H, dd, J=11.2Hz& J=2.2Hz), 6.29(1H, m), 5.29(2H, s), 4.93(2H, m), 4.55(2H,m), 4.56(2H,s), 3.86(2H, s), 3.85(4H, m), 3.09(4H, m), 2.5(1H, m)
Intermediate 20:
Step-1
To a cooled solution of thiazol-5-ylmethanol (5g, 43.4 mmol) in DCM (50 ml) at 0°C , TEA (12.10 ml, 87 mmol) was added dropwise followed by Ms-Cl (4.40 ml, 56.4 mmol) at same temp. The reaction mixture was stirred at rt for 4 hrs till SM vanished on TLC. Quenched with Water & extracted with EtOAc to get Crude, was purified by column chromatography to obtained 1.58 g liquid compound (Yield 18.8%). Mass m/z 194.235 [M+H]+
Step-2
To a solution of thiazol-5-ylmethyl methanesulfonate (0.1 g, 0.518 mmol) in DMF (2 ml), was add SODIUM AZIDE (0.067 g, 1.035 mmol) and leave the reaction to stir at room temperature for 20 h. Dilute the reaction mixture by the addition of water and extract with EtOAc .Wash the combine organic layers with brine. Dry over Na2SO4 and filter. Remove the solvent in vacuo and purify the crude by flash column chromatography to obtained 0.065 g liquid compound (yield 90%). Mass m/z 141.164 [M+H]+
Step-3
To a solution of 5-(azidomethyl)thiazole (3.13 g, 22.33 mmol) in THF (30 ml) & Water (9.00 ml), triphenylphosphine (7.61 g, 29.0 mmol) was added at rt, reaction mixture was stirred at r.t , SM vanished in 2 hrs. Acid-Base Workup : Quenched Solvent was evaporated at high vacuum, HC1 added to remaining aqueous solution to make a salt, washed with EtOAc to remove PPh3 & PPh3O multiple time, aqueous was separated & Basify to ppt the Amine, was extracted in DCM, Combine layer was passed through hyflow to remove emulsion & aqueous Layer was saturated by adding NaCl to facilate Extraction of Amine to DCM, Solvent was evaporated to dryness, Product was stored under -20°C to obtained 0.56 g off white liquid. (Yield 21.97 %). Mass m/z 115.166 [M+H]+
Step-4
Synthesis of methyl 4-nitro-3-((thiazol-5-ylmethyl)amino)benzoate
To a solution of methyl 3-fluoro-4-nitrobenzoate (30 mg, 0.151 mmol) & [Reactants] in DMF (1 ml), was added TEA (0.063 ml, 0.452 mmol) at 20°C. The reaction mixture was stirred at same temp for 2 hrs. Workup: Diluted with water & extracted with EtOAc & purified by column chromatography.to obtained 42.0 mg light yellow solid compound (yield 95%). Mass m/z 294 [M+H]+
Step-5
To a solution of [Products] in EtOH (10ml) & Water (4.00 ml) system solvent, IRON (0.876 g, 15.68 mmol) & ammonium chloride (0.839 g, 15.68 mmol) was added at R.T. & heated at 70°C for 3 hrs. Workup : After completion , Solution was filtered through Hyflow, rinsed with (1: 1) MeOH:DCM , Filtrate was evaporated at high vacuum, residue was dissolved in water & compound was extracted in EtOAc & purified by combiflash column to obtained 0.35 g light yellow solid compound (yield 40.7 %). Mass m/z 264 [M+H]+
Step-6
To A solution of methyl 4-amino-3-((thiazol-5-ylmethyl)amino)benzoate (350 mg, 1.329 mmol) & 2-chl oro-1, 1,1 -trimethoxyethane (370 mg, 2.393 mmol) in Acetonitrile (4 ml), /?-toluenesulfonic acid monohydrate (50.6 mg, 0.266 mmol) was added as catalyst at r.t. & RM was refluxed at 80°C for 7 hrs. Workup: Quenched with water & extracted with EtOAc quantitatively, crude was purified by column chromatography.to obtained 215 mg off white solid (yield 50.3 %). Mass m/z 322 [M+H]+.
Screening small molecule GLP-1R agonist using cAMP assay
To identify GLP-1R agonist, a cell based cAMP measurement assay has been used. Briefly, CHO-hGLP-lR (stably expressing full length human GLP-1R) were routinely maintained in complete DMEM media containing 800 pg/ml Neomycin. On day 1, 50,000 cells/well were seeded in 96 well cell culture plate. Next day, seeding media was completely aspirated and cells were primed with (100 pl/well) plain media (without FBS) containing 0.1% BSA, 100 pM and 3 pM BETP (2-(Ethylsulfinyl)-4-[3- (phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine) for 30 mins in humidified CO2 incubator. This was followed by addition of 2X drug solution (100 pl/ well) made in the same priming media and incubated for another 30 mins in humidified CO2 incubator. After that, cells were lysed (20 pl/well) with lysis buffer (Tris-Cl, pH 8.0, 150 mM NaCl and 0.1% Triton-X 100) for 20 mins on a plate shaker at RT. To clarify, lysate was centrifuged for 10 min at 4000 rpm at RT. Finally, 10 pl of lysate was used for cAMP measurement using cAMP Gs dynamic kit (Cis Bio, cat no: 62AM4PEB) according to the manufacturer’s protocol. % cAMP stimulation was measured with respect to the vehicle containing 0.4% DMSO.
In one of the embodiments compound of formula (I) of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
The compounds of formula (I) or pharmaceutical compositions containing them are suitable for humans and other warm blooded animals, and may be administered either by
oral, topical or parenteral administration for the treatment of various disease conditions as described hereinbefore.
The pharmaceutical composition is provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula (I) according to this invention.
The quantity of active component, that is, the compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
Thus, a pharmaceutical composition comprising the compounds of the present invention may comprise a suitable binder, suitable bulking agent &/or diluent and any other suitable agents as may be necessary. Optionally, the pharmaceutical composition may be suitably coated with suitable coating agents. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Claims
Wherein, X is selected from N, CH or -CF;
Y is selected from hydrogen, halogen, -CN, alkyl and haloalkyl; m is selected from 1, 2, 3 and 4;
2. Compounds of formula (I) as claimed in claim 1 are selected from:
(S)-2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((2-fluoro-4-isocyanobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((3-methoxyoxetan-3- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-3-(2-methoxyethyl)-3H- imidazo[4,5-b]pyridine-5-carboxylic acid;
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(thiazol-5-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5- dihydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,5-dihydropyrrolo[3,4- c]pyrrol-2(lH)-yl)methyl)-l -((1 -ethyl- IH-imi dazol-5-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-((l-ethyl-lH-imidazol-5- yl)methyl)-lH-benzo[d]imidazole-6-carboxylic acid;
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(4-((2-fluoro-4-isocyanobenzyl)oxy)pyrimidin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(2-methoxyethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo-imidazole-6- carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridine-5- carboxylic acid;
(2-((2-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
(S)-2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH-benzo[d]imidazole-6- carboxylic acid compound with 2,2,2-trifluoroacetic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((5-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-5,6-dihydropyrrolo[3,4- c]pyrazol-2(4H)-yl)methyl)-l-((3-methoxyoxetan-3-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
(S)-2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6- dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)methyl)-l-(oxetan-2-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((2-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((2-(2-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-4-yl)-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl)methyl)-l-(2-methoxyethyl)-lH-benzo[d]imidazole-6- carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyrazin-2-yl)-3,3a,4,6a- tetrahydrocyclopenta[c]pyrrol-2(lH)-yl)methyl)-l-(((S)-oxetan-2-yl)methyl)-lH- benzo[d]imidazole-6-carboxylic acid;
2-((5-(2-((4-chloro-2-fluorobenzyl)oxy)pyrimidin-4-yl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)methyl)-l-(oxetan-3-ylmethyl)-lH- benzo[d]imidazole-6-carboxylic acid.
3. Pharmaceutical composition comprising compound of general formula (I) as claimed in claim 1 , their tautomeric forms, their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
Use of the compounds as claimed in claim 1 for the treatment of T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YO D, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson’s Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, and addiction, by administering a therapeutically effective & non-toxic amount of the compound of formula (I), or their pharmaceutically acceptable compositions to the mammals. Method of treating T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar
craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson’s Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, and addiction in a subject which comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 or its suitable pharmaceutical composition. Compound of formula (I) as claimed in claim 1 in combination with other therapeutic agents selected from FXR agonist and semi-synthetic bile acid analogue, ACC inhibitor, Dual CCR2 and CCR5 antagonist, Thyroid hormone receptor beta agonist, MAPK5/ ASK-1 inhibitor, SGLT-2 inhibitor, Glucagon-like peptide- 1 (GLP-1) receptor agonist, Glucagon-like peptide- 1 (GLP-1) mimetics, PPAR a/5 agonist, Stearoyl Coenzyme A Desaturase 1 (SCD1) inhibition- Synthetic fatty acid-bile acid conjugate, Caspase inhibitor, metformin, sulfonyl ureas, long chain fatty acid agonists (GPR40, GPR120), DPP4 inhibitors, insulin sensitizer, Bempedoic acid or pharmaceutically acceptable salts.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202221044573 | 2022-08-04 | ||
IN202221044573 | 2022-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024028795A1 true WO2024028795A1 (en) | 2024-02-08 |
Family
ID=89848842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/057846 WO2024028795A1 (en) | 2022-08-04 | 2023-08-03 | Heterobicyclic compounds as oral glp1r agonists |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024028795A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
-
2023
- 2023-08-03 WO PCT/IB2023/057846 patent/WO2024028795A1/en active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7017521B2 (en) | Inhibitor of activin receptor-like kinase | |
CN114728940A (en) | GLP-1 receptor agonists and uses thereof | |
KR20210152513A (en) | GLP-1R agonists and uses thereof | |
KR102007056B1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
JP2022518860A (en) | Immunomodulators, compositions and their uses | |
JP2021152064A (en) | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | |
US9956220B2 (en) | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | |
US10933063B2 (en) | Bruton's tyrosine kinase inhibitors | |
CN109575022B (en) | Compound and application thereof | |
AU2014400628A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
WO2007037534A1 (en) | 2-heteroaryl-substituted indole derivative | |
CA3128846A1 (en) | Difluoromethylene compound | |
US11858918B2 (en) | GLP-1R modulating compounds | |
JP2017512796A (en) | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions containing them, and their antitumor applications | |
WO2014100540A1 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
EP3759095A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
US20220125787A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
TW202204351A (en) | Compounds having a macrocyclic structure and uses thereof | |
CN111094244B (en) | Pyridinylpyridinone compounds | |
CA3162281A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
EP4061817A1 (en) | Adenosine receptor antagonist compounds | |
WO2024028795A1 (en) | Heterobicyclic compounds as oral glp1r agonists | |
AU2021218952A1 (en) | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | |
CN111247144B (en) | Azaindolylpyridone compounds and diazaindolylpyridone compounds | |
TWI833819B (en) | Compounds and compositions for treating conditions associated with apj receptor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23849609 Country of ref document: EP Kind code of ref document: A1 |